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Abstract

The intent of this dissertation is to make a contribution to the field of pharmacovigilance.
Pharmacovigilance, also known as post-marketing drug surveillance, is the process of
continued monitoring for adverse drug reactions (ADRs) after drugs are released into the
market. An ADR is a harmful or unpleasant reaction related to the use of a medical product.
ADRs were reported to be between the fourth and sixth leading cause of death in the United
States in 1994, accounting for 3-7% of medical hospital admissions. On account of the
practice of pharmacovigilance, Vioxx (Rofecoxib) and Avandia (Rosiglitazone) are
examples of high profile drugs that were suspended from the American or European
market.
To prevent these effects on human health, pre-marketing clinical trials are designed to test
drug safety and efficacy. Although clinical trials are extensive and last multiple years, rare
ADRs may not be detected, and others may occur on account of idiosyncratic
characteristics of individuals excluded from the evaluated sample.
To aid the pharmacovigilance process, automated methods for the identiﬁcation of strongly
correlated drug/ADR pairs from data sources such as adverse event reporting systems, or
Electronic Health Records (EHRs), have been developed. These methods however are
generally statistical in nature, and do not draw upon the large volumes of knowledge
embedded in the biomedical literature.
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In this dissertation I investigate the ability of scalable Literature Based Discovery (LBD)
methods to identify side eﬀects of pharmaceutical agents in a computationally automated
manner. LBD methods can provide evidence from the literature to support the plausibility
of a drug/ADR association, thereby assisting human review to validate the signal, which is
an essential component of pharmacovigilance. The hypothesis underlying this work is that
by combining signals mined from EHR data with biomedical domain knowledge, the
accuracy of side effects detection may be improved. This also addresses the lack of
causality assessment in existing statistical methods in pharmacovigilance practice.
My theoretical contribution is that by conducting automated abductive reasoning and by
estimating the strength of generated explanatory hypotheses the plausibility of a drug/ADR
signal can be assessed. I adapt and extend the original abductive reasoning process as
defined by Peirce in 19th century by stating that the strength of the explanations found for
an observation is a measure for its plausibility, rather than taking an observation as given.
Practical contributions to pharmacovigilance and informatics include the development of
methods to leverage the knowledge from biomedical literature, the detection of signals
from the EHR data and the subsequent evaluation using supporting evidence from the
literature on a large scale in an automated way, and the development of an improved
drug/ADR reference set. My contributions are not restricted to pharmacovigilance and as
such constitute a contribution to the field of informatics in general.
I demonstrate that my work has extended the state of the art in EHR-based
pharmacovigilance and contribute new ideas that pave the way for further studies with the
potential to further enhance the field of pharmacovigilance and drug safety.

iv

Table of Contents
Acknowledgements ............................................................................................................. ii
Abstract .............................................................................................................................. iii
Table of Contents ................................................................................................................ v
List of Tables .................................................................................................................... xii
List of Figures .................................................................................................................. xiii
Chapter 1: Introduction ....................................................................................................... 1
1. 1 Significance of Pharmacovigilance....................................................................... 1
1.2 Challenges in pharmacovigilance and suggested solutions ................................... 2
1.3 Dissertation structure ............................................................................................. 4
1.4 Key contributions ................................................................................................... 5
Chapter 2: Literature Review .............................................................................................. 7
2.1 Pharmacovigilance: post-marketing drug surveillance .......................................... 7
2.1.1 Pharmacovigilance definition and significance .................................................. 7
2.1.2 Pharmacovigilance workflow in related health departments .............................. 9
2.1.3 Pharmacovigilance data sources ....................................................................... 10
2.2 Pharmacovigilance methodology ......................................................................... 12
2.2.1 Statistical data mining from pharmacovigilance database ................................ 12
v

2.2.2 Taxonomic reasoning ........................................................................................ 17
2.3 Predicting drug side effect relations ..................................................................... 18
2.3.1 Machine learning algorithms ............................................................................ 18
2.3.2 Regression and correlation analysis .................................................................. 19
2.3.3 Mining literature to predict drug/ADR associations ......................................... 20
2.3.4 Statistical data mining from EHR for signal detection ..................................... 21
2.4 Pharmacovigilance challenges from my perspective ........................................... 23
2.5 Signal detection from EHR .................................................................................. 23
2.6 Expert clinical review and causality assessment in pharmacovigilance .............. 25
2.6.1 Expert clinical review in pharmacovigilance .................................................... 25
2.6.2 Assessment of causality .................................................................................... 26
2.7 LBD and literature NLP annotation tools ............................................................ 27
2.7.1 LBD and discovery patterns.............................................................................. 27
2.7.2 Literature NLP annotation tools........................................................................ 29
2.8 Semantic Vectors ................................................................................................. 30
2.8.1 Overview of semantic vectors ........................................................................... 31
2.8.2 Scalability and random indexing (RI) ............................................................... 32
2.9 Research opportunities ......................................................................................... 33
2.9.1 Active drug surveillance with EHR .................................................................. 33

vi

2.9.2 Using distributional semantic models to find
plausible drug/ADR associations ...................................................................... 33
Chapter 3: Chapter 3: Signal Detection from Outpatient Electronic Health Record
Data Using Statistical Mining ......................................................................... 35
3.1 Materials .............................................................................................................. 37
3.1.1 Clinical data warehouse (CDW) ....................................................................... 37
3.1.2 Medical language extraction and encoding system (MedLEE) ........................ 38
3.1.3 Side effect resource 2 (SIDER2)....................................................................... 38
3.1.4 Hierarchical relationships between concepts from UMLS knowledge base .... 38
3.1.5 MEDication-Indication (MEDI) ....................................................................... 39
3.2 Methods................................................................................................................ 40
3.2.1 Annotating the EHR data using MedLEE ......................................................... 40
3.2.2 Construct test data set ....................................................................................... 40
3.2.3 Retrieve co-occurrence data for SIDER2 test set ............................................. 41
3.2.4 Statistical algorithms......................................................................................... 41
3.2.4.1 Disproportionality analysis ............................................................................ 41
3.2.4.2 Other statistical algorithm based on co-occurrence ....................................... 41
3.2.5 Filtering indications .......................................................................................... 44
3.2.6 Performance evaluation .................................................................................... 44
3.3 Experimental design............................................................................................. 44
vii

3.4 Results .................................................................................................................. 45
3.4.1 Experiment dataset ............................................................................................ 45
3.4.2 Query the co-occurrence data for experiment datasets ..................................... 46
3.4.3 Statistical results ............................................................................................... 47
3.4.3.1 Performance results ........................................................................................ 47
3.4.3.1.1 Performance of statistical algorithms with original co-occurrence data ..... 47
3.4.3.1.2 Effects of potential ontology intervention .................................................. 48
3.4.3.1.3 Effects of MEDI intervention ..................................................................... 50
3.5 Discussion ............................................................................................................ 52
3.6 Conclusion ........................................................................................................... 54
Chapter 4: Using Knowledge Extracted from the Literature to
Identify Plausible Adverse Drug Reactions .................................................... 55
4.1 Materials .............................................................................................................. 55
4.1.1 MMB and SemMedDB ..................................................................................... 56
4.1.2 SIDER2 ............................................................................................................. 56
4.1.3 MEDication-Indication (MEDI) ....................................................................... 57
4.2 Methods................................................................................................................ 58
4.2.1 RRI .................................................................................................................... 58
4.2.2 PSI ..................................................................................................................... 63
4.2.2.1 Operations in PSI ........................................................................................... 63
viii

4.2.2.2 PSI training process ....................................................................................... 63
4.2.2.3 Inferring discovery patterns ........................................................................... 65
4.2.2.4 Applying discovery patterns to find possible ADRs ..................................... 66
4.3 Experimental design............................................................................................. 69
4.3.1 Experiment 1 design ......................................................................................... 70
4.3.2 Experiment 2 design ......................................................................................... 71
4.3.3 Performance measurements .............................................................................. 72
4.4 Results .................................................................................................................. 73
4.4.1Experiment 1 ...................................................................................................... 73
4.4.1.1 Inferring discovery patterns ........................................................................... 74
4.4.1.2 Performance ................................................................................................... 76
4.4.1.3 AUC ............................................................................................................... 76
4.4.1.4 Rediscovery results ........................................................................................ 78
4.4.2 Experiment 2 ..................................................................................................... 79
4.4.3 Plausibility evidence found by PSI discovery patterns approach ..................... 81
4.5 Discussion ............................................................................................................ 88
4.6 Conclusion ........................................................................................................... 96
Chapter 5: Toward a Reality-based Repository of Adverse Drug Reactions:
Comparing SIDER2 with Side Events Encountered in Practice ..................... 97
5.1 Materials ............................................................................................................ 100
ix

5.2 Methods.............................................................................................................. 101
5.2.1 Import SIDER2 and FAERS data in database ................................................ 101
5.2.2 Parsing drug and side effect terms using MetaMap ........................................ 101
5.2.3 Mapping between SIDER2 and FAERS ......................................................... 103
5.2.4 Retrieve number of reports for mapped SIDER2 drug-side effect pairs
and perform disproportionality analysis to find significant
SIDER2 drug/ADR associations ..................................................................... 104
5.2.5 Performance measure ...................................................................................... 105
5.3 Experimental design........................................................................................... 105
5.4 Results ................................................................................................................ 106
5.4.1 Concept extraction .......................................................................................... 106
5.4.2 Reported SIDER side effects .......................................................................... 107
5.4.3 Statistically significant drug/ADR pairs detected by
disproportionality measures ............................................................................ 108
5.4.4 Manual review sample drug/ADR pairs without case reports ........................ 109
5.5 Discussion .......................................................................................................... 110
5.6 Conclusion ......................................................................................................... 112
Chapter 6: Improving Signal Detection from the Electronic Health Records by
Using Literature Based Discovery ................................................................ 113
6.1 Experimental design........................................................................................... 113
x

6.2 Materials and Methods ....................................................................................... 114
6.2.1 Models selected for this study......................................................................... 114
6.2.2 Experimental reference standards and test dataset.......................................... 115
6.2.3 Performance metrics ....................................................................................... 116
6.3 Results ................................................................................................................ 117
6.3.1 Performance .................................................................................................... 117
6.3.2 AUC ................................................................................................................ 119
6.4 Discussion .......................................................................................................... 120
6.5 Conclusion ......................................................................................................... 121
Chapter 7: Key Findings, Innovation, Contributions, Future work and Conclusions..... 123
7.1 Overview and summary of key findings ............................................................ 123
7.2 Innovation .......................................................................................................... 124
7.3 Theoretical contribution ..................................................................................... 124
7.4 Practical contribution ......................................................................................... 125
7.5 Future work ......................................................................................................... 127
7.6 Conclusions ......................................................................................................... 127
References ....................................................................................................................... 129

xi

List of Tables
Table 2-1. Quantitative data mining procedures used as
disproportionality measures in SRS .........................................................15
Table 3-1. Overall error measure in FDR approach ...................................................43
Table 3-2. Top 10 clinical documentation types in the EHR system.........................46
Table 3-3. Number of false pairs that have been excluded as indications .................51
Table 4-1. Different groups by extending MEDI in experiment 2 ............................72
Table 4-2. The most frequent predicate paths in
inferred discovery patterns ........................................................................74
Table 4-3. Results of precision and rank-based measures
for different groups ...................................................................................76
Table 4-4. PSI-double+triple model performance across all tests
with different MEDI lists ..........................................................................80
Table 4-5. Reasoning pathways used to retrieve evidence from the
literature for the pair rosiglitazone -- myocardial infarction ...................82
Table 4-6. Some example predications for possible mechanism of
rosiglitazone causing myocardial infarction ............................................83
Table 5-1. The percentage of statistically significant SIDER2
drug/ADR pairs using disproportionality measures .................................109
Table 6-1. SIDER2 and a Reference Set are used to construct the dataset
for the experiment .....................................................................................115
Table 6-2. Results of precision and rank-based measures for
different groups and different datasets ......................................................117

xii

List of Figures
Figure 2-1. Number of adverse event reports reported to FDA
from 2001 to 2011 ...................................................................................9
Figure 2-2. FDA pharmacovigilance process ............................................................11
Figure 3-1. The example ancestor-offspring hierarchy relationships
between UMLS concepts ........................................................................39
Figure 3-2. Comparison of ability of different performance metrics to recover
SIDER2 side effects for different statistical algorithms with different
drug/ADR co-occurrence threshold .........................................................48
Figure 3-3. Comparison of the predicted drug/ADR association count comparing
between original and descendant co-occurrence set ...............................49
Figure 3-4. Comparison of ability of different performance metrics to recover
SIDER2 side effects for different statistical algorithms with
different co-occurrence set ......................................................................50
Figure 3-5. Comparison of the predicted drug/ADR association count
comparing between different MEDI filtering indications .......................51
Figure 3-6. Comparison of ability of different performance metrics to
recover SIDER2 side effects for different statistical algorithms
after filtering indications by different MEDI lists ..................................52
Figure 4-1. The pseudo code for RRI model training process ...................................62
Figure 4-2. Schematic representation of RRI training and inference process ...........62
Figure 4-3. The Pseudo code for PSI model training process....................................65
Figure 4-4. Schematic representation of PSI training and inference process ............68
Figure 4-5. Experimental design in the detection of SIDER2 known
ADRs using LBD distributional semantic models ...................................69
Figure 4-6. ROC plot of true positive rate and false positive rate
for all groups ...........................................................................................77
xiii

Figure 4-7. Performance of AUC for all drugs by PSI-double+triple group .............78
Figure 4-8. Rediscovery plot for experiment groups .................................................79
Figure 4-9. The predications retrieved by reasoning pathway for rosiglitazone
causing myocardial infarction with specifying semantic
groups for concepts .................................................................................85
Figure 4-10. Middle terms that were retrieved by PSI discovery patterns
involving LDL-C ..................................................................................87
Figure 5-1. The procedure for mapping SIDER2 and FAERS ..................................103
Figure 5-2. Procedure of mapping SIDER2 drugs/side effects to FAERS
drugs/reactions using “dipyridamole” as an example .............................104
Figure 5-3. Study design for decreasing false SIDER2
drug-side effect associations ...................................................................106
Figure 5-4. Frequency distribution of number of SIDER2 drug/ADR pairs
grouped by the number of FAERS reports that contain the
drug/ADR of interest...............................................................................108
Figure 5-5. Interpretation of 60 randomly selected SIDER2 pairs without
any supporting reports..............................................................................110
Figure 6-1. Overall research design for reranking statistically significant
drug/ADR associations by similarity scores ...........................................114
Figure 6-2. Comparing accumulated number of true positives for each ranking
between pre- and post-reranking signals for
SIDER2 set and the Reference set ..........................................................118
Figure 6-3. ROC plot of true positive rate and false positive rate
for pre- and post-reranking groups for SIDER2 set ................................119
Figure 6-4. ROC plot of true positive rate and false positive rate
for pre- and post-reranking groups for Reference set .............................120
Figure 6-5. The proposed architecture for a plausibility-based
pharmacovigilance system ......................................................................122

xiv

Chapter 1: Introduction
1.1 Significance of Pharmacovigilance
An adverse drug reaction (ADR) is an “appreciably harmful or unpleasant reaction,
resulting from an intervention related to the use of a medical product” (Edwards &
Aronson, 2000). ADRs contribute to substantial morbidity, health care visits and hospital
admissions (Baker et al., 2004; Chan, Nicklason, & Vial, 2001; Hamilton, Briceland, &
Andritz, 1998; Lazarou, Pomeranz, & Corey, 1998; Pirmohamed et al., 2004). For
example, ADRs were reported to be between the fourth and sixth leading cause of death in
the United States in 1994 (Lazarou et al., 1998), accounting for 3-7% of medical hospital
admissions (Baker et al., 2004; Hamilton et al., 1998) and a substantial number of health
care visits (Bourgeois, Mandl, Valim, & Shannon, 2009). A recent observational study
conducted in two emergency departments shows that 8.9% of emergency patients had a
probable ADR (Capuano et al., 2004). Overall, they have a considerable negative impact
and place an enormous burden on both health and healthcare system (Pirmohamed et al.,
2004; Rodríguez-Monguió, Otero, & Rovira, 2003) and consequently constitute a notable
public health problem (Capuano et al., 2004).
To prevent these harmful effects on human health, pre-marketing clinical trials are
designed to test drug safety and efficacy. Phase III clinical trials have been estimated to
cost 86.3 million US dollars and last 30.5 months on average (DiMasi, Hansen, &
Grabowski, 2003). Nonetheless, rare ADRs may not be detected due to the limited duration
1

and sample size of such trials, and others may occur on account of idiosyncratic
characteristics of individuals excluded from the evaluated sample. The continued
monitoring for ADRs after drugs are released into the market, referred to as
pharmacovigilance (also known as post-marketing drug surveillance), is therefore an
important tool to monitor and improve drug safety (Mann & Andrews, 2007). For example,
on account of the practice of pharmacovigilance, Vioxx (Rofecoxib) was withdrawn
voluntarily worldwide in 2004 because of the finding of increased risk of heart attack
(Merck, 2004). Similarly, Avandia (Rosiglitazone) was suspended from the European
market in 2010 by the European Medicines Agency (EMA) (FDA, 2011; Ye, 2011).

1.2 Challenges in pharmacovigilance and suggested solutions
Over the last decade, the World Health Organization (WHO), the Food and Drug
Administration (FDA), EMA and others instituted spontaneous reporting systems (SRSs)
for the systematic collection of ADR reports (Rawlins, 1988a). Drug safety data obtained
from SRSs have been analyzed using quantitative data mining procedures to retrieve
strongly associated drug/ADR pairs (Puijenbroek, Diemont, & van Grootheest, 2003;
Rawlins, 1988a, 1988b). These highlighted associations are subsequently reviewed and
scrutinized by domain experts. These are essential parts of a pharmacovigilance system,
which are referred to as drug/ADR signal detection and evaluation (A. Bate et al., 1998; A.
Bate, Lindquist, Edwards, & Orre, 2002; Bates, Lindquist M., Orre R., Edwards I., &
Meyboom R., 2002).
There are two major problems with these processes. First, research suggests data collected
by SRS are limited by long time latency, incorrect or incomplete clinical information,
2

underreporting and reporting bias (Rawlins, 1988a, 1988b; Hasford, Goettler, Munter, &
Müller-Oerlinghausen, 2002; Alvarez-Requejo et al., 1998). Second, it has been argued
that causality assessment is lacking in pharmacovigilance practice (Anderson & Borlak,
2011). The WHO defines causality assessment as the evaluation of the likelihood that a
medicine caused the observed adverse event (WHO-Uppsala Monitoring Centre, 2013).
The lack of this evaluation is due to the expense and time involved in manual review by
domain experts. In practice resources are too limited for the large number of signals
produced by SRSs.
A potential workaround to the resource limitations is to use information from other sources
to supplement SRSs. Drug intake and symptoms are documented by clinicians in EHR data,
although the rate of false positives is expected to be high because the number of possible
adverse events is small compared to the number of desired treatment outcomes. After
filtering known drug indications a causality assessment of statistically significant signals
is necessary to identify possible side effects. Potential and known mechanisms of action
are described in detail in the biomedical literature. It is therefore possible to leverage
domain knowledge from biomedical literature to make statements about the plausibility of
drug/ADR connections. The hypothesis underlying this work is that by combining signals
mined from EHR data with biomedical domain knowledge, the accuracy of side effect
detection may be improved.
I evaluate this hypothesis in a series of experiments, First, I apply disproportionality
measures and Chi-square test to analyze drug-event co-occurrence data derived from EHR
to find statistically significant drug/ADR associations and evaluate the performance of
these statistical algorithms. For the statistically significant drug/ADR associations, I apply
3

scalable methods of literature-based discovery (LBD) (Hristovski, Friedman, Rindflesch,
& Peterlin, 2006; Kostoff, Briggs, Solka, & Rushenberg, 2008; Swanson, 1986b)
leveraging methods of distributional semantics (Cohen, Schvaneveldt, & Widdows, 2010;
Cohen, Widdows, Schvaneveldt, Davies, & Rindflesch, 2012; Widdows & Cohen, 2010)
to evaluate the plausibility of their connections. I do this by utilizing knowledge from the
published literature to automatically generate explanatory hypotheses which collectively
contribute to a plausibility score and a subsequent reranking according to their plausibility.
This also alleviates the problem of an overwhelming amount of associations for manual
expert review.
During the course of this research, it came to my attention that there is no agreed-upon gold
standard in pharmacovigilance (Tatonetti, Ye, Daneshjou, & Altman, 2012). This may
affect the performance evaluation because of the existing false drug/ADR associations in
the reference data. So a reference set was developed and used for additional performance
evaluation in this study.
To reiterate, the unifying hypothesis that is tested in the dissertation is that drug/ADR
signal detection from EHRs can be improved by integrating knowledge from the
biomedical literature.

1.3 Dissertation structure
This dissertation is structured as follows. In Chapter 2, I review literature related to the
field of and recent research in pharmacovigilance as well as LBD methods and
distributional semantics. In the following chapters I perform a series of experiments to
evaluate my hypotheses. In Chapter 3, I describe the first experiment, in which statistical
4

mining algorithms are used to find statistically correlated drug/ADR associations from
EHR data. In Chapter 4, I build LBD based distributional semantic models to identify
plausible ADRs using knowledge extracted from the literature. In Chapter 5, a drug/ADR
association reference set is built as a subset of a dataset containing known side effects. The
subset contains only those associations that are confirmed to be statistically significant
using data from an SRS. In Chapter 6, I evaluate the effects of plausibility based reranking
on the precision of the statistically significant drug/ADR associations detected in EHR
data. In this experiment, two reference sets are utilized and the performance against these
sets is compared. The dissertation concludes with describing its significance and
contributions to the field of pharmacovigilance, informatics and public health.
1.4 Key contributions
The purpose of this dissertation is to automatically identify drug/ADR associations that are
most likely causal among those signals detected from EHR with statistical methods by
integrating domain knowledge from the biomedical literature that is related to side effects.


A surprising drug/ADR signal (surprise observation) is detected from an EHR
system.



There is a genuine doubt about this observation (doubt).



To resolve the doubt, an inquiry is initiated (inquiry) by searching the literature to
support plausible connections between the drug and the ADR.



Supporting plausibility evidence is subsequently utilized as sufficient explanation
(explanation) to relieve the doubt about the surprising observation.

My theoretical contribution is that by conducting automated abductive reasoning
(Josephson & Josephson, 1996; Locke, Golden-Biddle, & Feldman, 2008; Peirce, 1955;
5

Schvaneveldt & Cohen, 2010) and by estimating the strength of generated explanatory
hypotheses the plausibility of an observation (in this work, a drug/ADR signal) can be
assessed. This means that I adapt the original abductive reasoning process by stating that
the strength of the explanations found for an observation is a measure for its plausibility.
A low plausibility likely implies that an observation is a false positive and should be
considered for rejection. A high measure of plausibility on the contrary supports the
validity of the observation.
This differs from the original line of thought by introducing a measure to assess plausibility
rather than taking the observation as a given fact.
The practical contributions to pharmacovigilance and informatics are as follows:


The development of methods to leverage knowledge from the literature as a
means to assess the plausibility of observations from EHR data.



The detection of signals from EHR data and the subsequent evaluation using
supporting evidence from literature in pharmacovigilance on a large scale in an
automated way.



The development of a drug/ADR reference set based on both an established side
effects repository and a high volume drug/ADR data set from an SRS.



The methods and procedures of integrating formal knowledge can be generalized
and applied to other domains, such as outbreak detection, for which a timely
identification of plausibility for signals is essential. This is not restricted to
pharmacovigilance and constitutes a contribution to the field of informatics in
general.

6

Chapter 2: Literature Review
2.1 Pharmacovigilance: post-marketing drug surveillance
2.1.1 Pharmacovigilance definition and significance
Vioxx (Rofecoxib) was withdrawn voluntarily from market by Merck in 2004, after it was
found that the use of this agent increased the risk of myocardial infarction (Merck, 2004).
Graham et al (Graham et al., 2005) estimated that between 88,000 and 140,000 excess
serious coronary heart diseases might have been caused by rofecoxib in the US since it was
launched in 1999. Avandia (Rosiglitazone) was suspended from the European market in
2010 (Blind, Dunder, Graeff, & Abadie, 2011; EMA, 2010; Ye, 2011) on account of an
increased risk of cardiovascular complications. These high-profile examples illustrate that
pharmacovigilance is very important to supplement existing drug safety profiles because
clinical drug trials cannot be large or long enough to identify all problems related to a new
drug (Rawlins, 1988a). Additionally, subjects are pre-selected by eligibility criteria and
therefore may not fully represent the patient population after the drugs are put to market
(Anderson & Borlak, 2011). Besides, some patient may have idiosyncratic drug reactions
which cannot be explained by the pharmacological effect of the drug (Knowles, Uetrecht,
& Shear, 2000). Consequently, it is highly unlikely that instances of all possible ADRs will
be detected during pre-marketing clinical trials.
To address this problem, health departments and organizations (such as the World Health
Organization (WHO), United States Food and Drug Administration (FDA), and European
7

Medicines Agency (EMA)) encourage physicians, other health care professionals, and
patients to report voluntarily about any observed ADRs. In addition to voluntarily
reporting, pharmaceutical companies are mandatory required to report serious adverse
events (Ahmad, 2003). These bodies have Spontaneous Reporting Systems (SRS) to enable
the efficient submission of reports electronically (Kessler et al., 1993; Wysowski & Swartz,
2005).
Since 1969, the FDA Adverse Event Reporting System (FAERS), which provides the
means for clinicians to report suspected adverse events electronically, collected more than
7 million case reports (Fine, 2013) and the number of ADR reports submitted to the FDA
continues to grow (Figure 2-1). More than 75 drug products have been removed from the
market due to safety problems from 1969 to 2002 (Wysowski & Swartz, 2005). The facts
emphasize

the

importance

of

post-marketing

drug

monitoring,

known

as

pharmacovigilance – “the science and activities relating to the detection, assessment,
understanding and prevention of adverse effects or any other drug-related problem after
drugs are on market” (WHO, 2010). Pharmacovigilance is designed to detect any rare or
long-term adverse effects over a very large population and a long period of time.

8

Figure 2-1: Number of adverse event reports reported to FDA categorized by reporter
(top left), by patient outcome (top right), by geographic sources (bottom left) and by
types of reports (bottom right) from 2001 to 2011

2.1.2 Pharmacovigilance workflow in related health departments
In general, the pharmacovigilance process proceeds as follows (Andrew Bate, 2003;
Edwards, 1992; Lindquist et al., 1999):
(1) Reported drug-related problems are collected in SRSs nationally or internationally;
(2) Quantitative data mining procedures are used to analyze these data and retrieve
relatively strongly correlated drug/ADR pairs (drug/ADR associations);

9

(3) These highlighted associations are then reviewed and evaluated by domain experts
making up an expert clinical review panel; and
(4) Associations considered to be of clinical interest are then annotated as “signals”.
Specifically, signal is defined as “reported information on a possible causal relationship
between an adverse event and a drug, the relationship being unknown or incompletely
documented previously” (Edwards & Biriell, 1994; van Puijenbroek et al., 2002). Overall,
the pharmacovigilance process in WHO (Andrew Bate, 2003), FDA (Fine, 2013; Gould,
2005) and EU-ADR initiative (P. Lopes et al., 2013) includes two components -- a
statistical component (quantitative signal detection, steps (1) and (2)) and a qualitative
component (expert clinical review, steps (3) and (4)) (Andrew Bate, 2003). Figure 2-2
demonstrates the specific pharmacovigilance workflow in FDA.
2.1.3 Pharmacovigilance data sources
Through pharmacovigilance, international and national health institutions gather large
amount of data mainly from SRS for further analysis. In addition to case reports,
specialized networks and active surveillance data are also considered as data sources for
detecting safety signals, even though they are in experimental phrases (FDA Science Board
Subcommittee, 2011). Specialized networks, such as the Drug Induced Liver Injury
Network (DILIN) (Hoofnagle, 2004), focus on collecting side effects data concerning
specific organ targets, patterns of ADRs or patient populations. Active surveillance efforts,
such as Sentinel Network (Platt et al., 2009; Platt, Madre, Reynolds, & Tilson, 2008) and
Observational Medical Outcomes Partnership (OMOP) (Stang et al., 2010), utilize existing
systems for the purpose of drug monitoring (U.S. Food and Drug Administration, 2008).
Examples of potentially useful systems include EHRs, pharmacoepidemiological databases
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(Johansson, Wallander, de Abajo, & Rodriguez, 2010), health insurance claims databases
(Brown et al., 2007, 2009), and so forth. the Observational Medical Outcomes Partnership
(OMOP) uses EHR and other data sources to identify ADR signals and the preliminary
results demonstrate that active surveillance from EHR systems can complement current
pharmacovigilance practice, but also that performance varies by data source, drug and
outcomes of interest (FDA Science Board Subcommittee, 2011).

Figure 2-2: FDA pharmacovigilance process – adapted from (Fine, 2013; Gould, 2005)

With the opportunity presented by EHRs’ broader availability, researchers have also used
EHR data for drug safety research and have attempted to demonstrate that EHR data are a
relevant and significant data source for pharmacovigilance (Collins, 2011; Wang,
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Hripcsak, Markatou, & Friedman, 2009). These authors argue that EHR data can
compensate for some of the deficiencies of SRS, such as under-reporting, misclassification,
a long lag time between observation and reporting, reporting bias and the provision of
incomplete background clinical information (Rawlins, 1988a, 1988b).

2.2 Pharmacovigilance methodology
2.2.1 Statistical data mining from pharmacovigilance database
Statistical algorithms are routinely applied to SRSs (A. Bate et al., 1998; W. DuMouchel
& Pregibon, 2001; W DuMouchel, 1999; Lindquist et al., 1999; Lindquist, Stahl, Bate,
Edwards, & Meyboom, 2000; Noren, Bate, Orre, & Edwards, 2006) to measure the strength
of reported drug-event associations. Quantitative data mining procedures are measuring
“disproportionality”. Reporting disproportionality is defined as a statistically significant
higher reporting frequency of particular drug/ADR associations compared with marginal
distributions of drugs and ADRs as a background in the reporting database (Shibata &
Hauben, 2011). These disproportionality measures quantify how often a drug and a
possible event co-occur compared to the background reporting occurrence across all other
drugs and events using an independence model (Manfred Hauben, Madigan, Gerrits,
Walsh, & Van Puijenbroek, 2005). The reporting of the event related to other drugs in the
database is used as a proxy for the background occurrence of the event (Poluzzi, Raschi,
Piccinni, & De Ponti, 2012). To put it in another way, different disproportionality measures
quantify the extent to which a given event is frequently reported with a given drug by
estimating the observed-to-expected co-occurrence ratio. Those drug-event pairs that are
significantly different from background reporting occurrence may reflect credible signals
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that need further investigation. However, reported ADRs do not necessarily accurately
reflect the usage of drugs and the incidence of ADRs in the population (Poluzzi et al.,
2012), the significant pairs may represent reporting tendencies (Manfred Hauben & Reich,
2005). Commonly used disproportionality measures include the proportional reporting
ratio (PRR) (Evans, Waller, & Davis, 2001), the reporting odds ratio (ROR) (Puijenbroek
et al., 2003), Bayesian confidence propagation neural network (BCPNN, information
component (IC) is the statistical score) (A. Bate et al., 1998; Lindquist et al., 1999, 2000;
Noren et al., 2006), multi-item gamma Poisson Shrinker (MGPS, empiric Bayes geometric
mean (EBGM) is the statistical score) (W. DuMouchel & Pregibon, 2001; W DuMouchel,
1999), and others (Table 2-1). Different comparison references are used to estimate the
expected ADR occurrences in frequency probability based measures. The observed for all
drugs and the observed for all other drugs are used to estimate the expected occurrence of
the ADR for PRR and ROR respectively (Poluzzi et al., 2012). With Bayesian methods, if
a drug and an ADR is independent, then their joint probability to the product of the
individual probabilities will equal to 1 (Poluzzi et al., 2012). This inference hypothesis is
used to calculate and interoperate observed-to-expected co-occurrence ratio. Roux et al.
(E. Roux et al., 2003) evaluated these statistical models on simulated datasets (constructed
by SRS modeling for arbitrary selected 150 drugs and 100 side effects) by comparing the
percentage of false positive signals among given drug-event combinations (Emmanuel
Roux, Thiessard, Fourrier, Begaud, & Tubert-Bitter, 2005). The false positive rates varied
from 1.1% to 53.4%; and EBGM, IC and Chi-square models seemed to have better
performances (Emmanuel Roux et al., 2005). Puijenbroek et al. (van Puijenbroek et al.,
2002) also evaluated different measures and found out that sensitivity was high with respect
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to the reference measure when a combination of point- and precision estimates was used.
For example, in the PRR measure, the PRR is the point estimate; and its lower limit of 95%
Confidence Interval (CI) is the precision estimate.
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Table 2-1: Quantitative data mining procedures used as disproportionality measures in SRS (Balakin & Ekins, 2009; M. Hauben &
Bate, 2009; Manfred Hauben et al., 2005; Emmanuel Roux et al., 2005; van Puijenbroek et al., 2002)
Reports with the suspected event j
Reports with the drug i of interest

a(=nij)

b

c

d

Reports with all other drugs
Measure of Association and Data
source

Reports without the suspected event j

Measure of importance

Formula

Probabilistic
Interpretation

Frequentist Approaches

15

Proportional Reporting Ratio (PRR)
(Evans et al., 2001)
UK Yellow Card database,
Medicines Control Agency (MCA)

PRR 

a /( a  b )

PRR  1 .96 SE  1

P( A | D)

c /( c  d )

or

P( A | D)

SE (ln PRR ) 

1

1

1

1

( 
 
)
a ab c cd

PRR  2, a  3,  2  4

95 % CI  e ln( PRR ) 1.96 SE (ln PRR )

Reporting Odds Ratio
(ROR) (Puijenbroek et al., 2003)

ROR 

Netherlands Pharmacovigilance
Centre Lareb

SE (ln ROR ) 

(a / c)
(b / d )



ROR  1.96 SE  1

ad

P( A | D)P( A | D  )

bc
(

1
a

P( A | D)P( A | D  )



1
b



1
c

95 % CI  e ln( ROR ) 1.96 SE (ln ROR )



1
d

)

Table 2-1: Continued
Measure of Association and Data
source

Formula

Measure of importance

Probabilistic
Interpretation

Bayesian Approaches
Relative Risk (RR)

IC  log 2

n ij

a
RR 

( a  b )( a  c )
E ij
abcd

a (a  b  c  d )

IC  2 SD  0

( a  b )( a  c )

WHO BCPNN and FDA MGPS
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RR 

a (a  b  c  d )
( a  b )( a  c )

EBGM 05  2

log 2

P ( A, D )
P ( A) P ( D )

 log 2

P( A | D)P(D)

 log 2

P( A | D)

P ( A) P ( D )
P ( A)

P( A | D)
P ( A)

A: ADR; D: Drug; BCPNN: Bayesian Confidence Propagation Neural Network; MGPS: Multi-item gamma Poisson Shrinker

2.2.2 Taxonomic reasoning
In addition to the use of quantitative techniques, ontology-based reasoning in combination
with quantitative data mining methods has been shown to be able to improve signal
detection from SRSs (J. S. Almenoff et al., 2007; Bousquet, Henegar, Louėt, Degoulet, &
Jaulent, 2005; Bousquet, Trombert, Kumar, & Rodrigues, 2008; Henegar, Bousquet, LilloLe Louët, Degoulet, & Jaulent, 2006; Mera, Beach, Powell, & Pattishall, 2010; Nadkarni,
2010). Different methods of ontological reasoning were conceived. Two examples, coined
terminological reasoning by subsumption and approximate matching (Bousquet et al.,
2005), are summarized in the following.
In a terminological hierarchy, when multiple subclasses are connected to one superclasses,
it is said that the superclass subsumes all of the subclasses. Reasoning by subsumption then
means that a given class and all of its subsumed classes are considered to be one entity.
The new entity then constitutes all of the signals of the individual classes into one,
increasing its number of occurrence. In SRSs, ADRs are usually coded using the Medical
Dictionary for Regulatory Activities (MedDRA) terminology, and MedDRA’s hierarchy
was used to facilitate terminological reasoning by subsumption.
In approximate matching, a new concept is built as the disjunction of all sets of possible
characteristics. For example, Hepatitis is defined as “((hyperbilirubinemia AND ALAT
increased) OR (ASAT increased AND cholestasis) OR (jaundice AND cytolysis))”
(Bousquet et al., 2005). This is another way to group cases to increase the number of
occurrences of identifiable drug/ADR associations.
These and other approaches and combinations of both approaches have been shown to
improve signal detection by exploiting ontological properties with statistical data mining
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methods (J. S. Almenoff et al., 2007; Bousquet et al., 2005, 2008; Mera et al., 2010;
Nadkarni, 2010).

2.3 Predicting drug side effect relations
2.3.1 Machine learning algorithms
Other researchers have attempted to predict which drugs cause which side effects using
machine learning approaches with structured knowledge concerning the drugs and ADRs
as features. Liu et al. applied five supervised machine learning (ML) algorithms with drug
features drawn from PubChem (chemical substructures), DrugBank (drug target,
transporters, and enzymes), KEGG (pathway) and SIDER itself (drug indication and side
effects). A ML classifier was built for each SIDER ADR. The classifiers were then
evaluated on 832 SIDER drugs (for which DrugBank IDs could be found) using five-fold
cross-validation. Of the algorithms evaluated, the support vector machine (SVM) algorithm
performed best with an AUC of 0.9054 on the SIDER dataset as a whole (Liu, Wu, et al.,
2012).
In other work (Huang, Wu, & Chen, 2011), the features were selected from drug-target
information from DrugBank and drug non-target protein information from an expanded
protein-protein interaction (PPI) network derived from gene ontology (GO) annotations. A
SVM classifier was built for each ADR and cross-validated on a known side effect resource
(SIDER, version 1).
In related work, decision tree models were derived for specific end organs using features
derived from the chemical structure of the agents in the SIDER set. The accuracies of
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decision trees for allergic, renal, central nervous system (CNS) and hepatic ADRs ranged
from 78.9% to 90.2% (Hammann, Gutmann, Vogt, Helma, & Drewe, 2010).
In addition to supervised ML algorithms, unsupervised learning using topic models has
also been used to analyze drug labels and group drugs by topics that are associated with
the same side effects (Bisgin, Liu, Fang, Xu, & Tong, 2011).
2.3.2 Regression and correlation analysis
Pauwels and colleagues applied sparse canonical correlation analysis (SCCA) utilizing the
chemical substructure of drugs to predict side effects (Pauwels, Stoven, & Yamanishi,
2011). Features representing drugs’ chemical substructures were extracted from PubChem.
Side effects were extracted from SIDER. Canonical correlation analysis (CCA) is a way of
measuring the linear relationship between two multidimensional variables and customized
to analyze the relationship between the group of chemical substructure and the group of
side effects and to find what chemical substructure can represent what side effect. Highly
correlated sets of chemical substructures and side effects were retrieved, and predictive
scores associating substructures to side effects were calculated. SCCA is a variant of
canonical correlation analysis that aims to minimize the size of the set of features utilized
so as to facilitate explanation. The AUC for SCCA is 0.8932 for predicting side effects.
In another study, logistic regression was used to predict ADRs using as features chemical
substances from PubChem and BioAssay (a database of bioactivity screens of chemical
substances). Performance was evaluated for side effects related to specific organ systems,
and was best for immune system disorders (AUC=0.92) and blood and lymphatic system
disorders (AUC=0.79) (Pouliot, Chiang, & Butte, 2011).

19

2.3.3 Mining literature to predict drug/ADR associations
Currently, systematic literature review is utilized as an in-depth investigation to provide
scientific evidence to confirm a specific drug/ADR relationship or support regulatory
decisions (for example, drug withdrawal) in the pharmacovigilance process (Arnaiz et al.,
2001; Y. K. Loke, Kwok, & Singh, 2011; Yoon K Loke, Price, & Herxheimer, 2007; P.
Lopes et al., 2013; Marie et al., 2008; Olivier & Montastruc, 2006). However, evidence in
the biomedical literature (e.g. case reports, clinical trials) may appear before an ADR is
recognized. This implies that analyzing the literature to predict drug/ADR associations may
complement current drug safety methods (disproportionality measures of SRS). This aspect
of pharmacovigilance has been explored in a few studies only (Alomar, Hourani, &
Sulaiman, 2008; Deftereos, Andronis, Friedla, Persidis, & Persidis, 2011; Shetty & Dalal,
2011).
There are two major investigative perspectives. One perspective involves using the
literature as a data source for ADR case reports, and then applying statistical models to
mine the drug/ADR associations (Alomar et al., 2008; Shetty & Dalal, 2011). Shetty et al.
(Shetty & Dalal, 2011) retrieved literature about side effects by searching PubMed using
NLM’s Medical Subject Headings (MeSH) index, and then filtering irrelevant articles (for
example articles discuss only treatments) using a Lasso-based document relevance
classifier (Genkin, Lewis, & Madigan, 2007). With the contingency table built from
drug/ADR occurrence across all relevant citations, a disproportionality analysis was
applied to find statistically significant drug/ADR associations. This model discovered 54%
of all detected FDA warnings from labeling and also confirmed the association between
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rofecoxib and heart disease with literature before 2002 while rofecoxib was recalled in
2004.
The second perspective is based on the paradigm of literature-based discovery (LBD), and
involves processing the literature to uncover indirect relationships between drugs and
ADRs. Using LBD for pharmacovigilance has not been attempted until recently Hristovski
et al. (Hristovski et al., 2006) model LBD discovery patterns to analyze semantic
predications and find therapeutic relations for drugs and a disease. To date, LBD-inspired
pharmacovigilance research has concerned providing justification for a connection
between a drug and an ADR, or investigating possible mechanisms to explain an observed
side effect using the literature (Ahlers, Hristovski, Kilicoglu, & Rindflesch, 2007;
Hristovski, Burgun-Parenthoine, Avillach, & Rindflesch, 2012a). However, this approach
has not yet been evaluated as a means to predict side effects on a large scale. I will elaborate
further on this aspect in Section 2.7.1.
2.3.4 Statistical data mining from EHR for signal detection
Using EHR data for pharmacovigilance is an active research area (Wang et al., 2009).
Disproportionality measures applied to SRSs have been applied to EHR data also (Zorych,
Madigan, Ryan, & Bate, 2011; Liu, McPeek Hinz, et al., 2012). However, these algorithms
were designed for reporting systems to evaluate whether a given event is disproportionally
“reported” with a given drug. As side effects may not be explicitly reported in the EHR,
the applicability of disproportionality measures to EHR data must still be evaluated
(Zorych et al., 2011). Zorych et al. (Zorych et al., 2011) hypothesize that the observed cooccurrence of a drug and an event can be regarded as though they were reported as a
spontaneous reporting case, to produce drug-event contingency tables. Using this
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approach, existing disproportionality algorithms were applied to both real world and
simulated EHR data. Results show that the disproportionality algorithms can find
legitimate drug/ADR associations; they also produce a large number of false positive
associations. Liu et al. (Liu, McPeek Hinz, et al., 2012) assessed disproportionality
measures on drug-laboratory test ADR associations derived from EHR data. This study
further demonstrated that disproportionality measures can be applied to analyze EHR data
for pharmacovigilance. Of note, these EHR data (Zorych et al., 2011; Liu, McPeek Hinz,
et al., 2012) were structured.
However, most clinical information also includes unstructured narratives, which contain
valuable patient data. Several researchers (Cao, Hripcsak, & Markatou, 2007; Cao,
Markatou, Melton, Chiang, & Hripcsak, 2005; Wang et al., 2009) have investigated
measuring co-occurrence within the narrative section of the EHR as a means to detect
possible drug/ADR associations. This is accomplished by calculating above-chance
occurrences of drug and problem pairs in the clinical notes, where each note represents a
clinical encounter. Associations among entities are estimated using statistical methods
(Chi-Square statistics) based on their co-occurrence statistics in the clinical notes. Cooccurrence statistics (Christopher D. Manning & Hinrich Schütze, 1999) have been
successfully applied in the computational linguistics domain, for example, for the purpose
of word sense disambiguation (Yarowsky, 1995), automatic generation of semantic
lexicons (Roark & Charniak, 1998) and synonym mining (Turney, 2001). In addition to
word-level co-occurrence statistics, concept-level co-occurrence has also been used to
discover associations between concepts (Cao et al., 2005). If a drug causes an ADR, then
this drug and this related problem are more likely to appear together than random
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combinations of drugs and adverse events in clinical notes (Cao et al., 2005). It has been
demonstrated that co-occurrence statistics can be derived from unstructured EHR data to
detect possible side effects (Wang et al., 2009).

2.4 Pharmacovigilance challenges from my perspective
The above review of the literature highlights two major challenges: inefficient and
incomplete SRS data and the lack of computer-assisted causality assessment in
pharmacovigilance practice. As discussed in section 2.1.3, EHR may compensate for the
limitations of SRSs and provide the opportunity for active surveillance. As argued in
(Anderson & Borlak, 2011), there is a lack of causality assessment in pharmacovigilance
practice. While expert clinical review is designed to verify potential ADRs, it is a humanintensive and time-consuming process. The available human resources are inadequate to
review the large amount of noisy signals detected in SRS and EHR data, creating a
bottleneck in the pharmacovigilance process. More research is needed to develop methods
to automate, or assist with, the knowledge-intensive task of expert clinical review. In the
section that follows, I will discuss emerging methodologies that I propose adapting in order
to address these limitations: EHR data can be used as an alternative data source for
pharmacovigilance and scalable LBD methods based on distributional semantics can be
utilized to assist signal evaluation.

2.5 Signal detection from EHR
An EHR system presents the possibility of a real-time, continuous approach to drug
surveillance (Brown et al., 2007; Trifirò et al., 2009; Wang et al., 2009). It has been
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estimated that Vioxx would have been withdrawn in just 3 months instead of 5 years if the
EHR data of 100 million patients had been available for drug monitoring (McClellan, 2007;
Pray, Robinson, & Translation, 2007; Trifirò et al., 2009; Wagner et al., 2006). In addition
to review the statistical mining from EHR (Section 2.3.4), I continue to review the recent
proposed framework using EHR for pharmacovigilance from a pilot study (Wang et al.,
2009).
Wang et al. (Wang et al., 2009) proposed a pharmacovigilance framework utilizing an EHR
system. The basic procedure is: (1) Drug-relevant data (both structured and unstructured)
are extracted from the EHR. A Natural Language Processing (NLP) tool is used to parse
free-text clinical notes because unstructured data may include richer patient information;
(2) The drug relevant data are coded and mapped to a standard terminology for further
analysis; (3) Drug and related event pairs are selected by filtering indication relationships
and excluding incorrect temporal order of events (i.e. side effect before drug
administration); (4) Selected drug-event pairs are analyzed using statistical data mining
algorithm (Chi-square statistics) to obtain a ranked ADR list for all respective drugs based
on the strength of the statistics; (5) For each drug’s ranked ADR list, an empirical threshold
of significance level is adjusted by volume tests using the P-value plot (Schweder &
Spjøtvoll, 1982; Cao et al., 2005, 2007; Wang et al., 2009) to determine possible signals
for each drug.
Essentially, there are two major tasks required to use EHR data for pharmacovigilance. The
first task is to process and clean EHR data to get drug-event combinations and retrieve
these combinations’ co-occurrence data using informatics tools. Second is to conduct
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statistical analysis to analyze these co-occurrence data of drugs and events to detect the
significant drug/ADR pairs.
ADR signals have relatively low incidence in comparison with background information in
the EHR (for example, therapeutic relationships are more common) because EHRs are not
designed for ADR monitoring. This leads to noise, which means the application of basic
statistical methods alone will detect many false signals. Thus estimating a threshold to find
stronger associations maybe difficult (Cao et al., 2007; Wang et al., 2009). However,
pharmacovigilance from EHR can provide good signal candidates for further investigation.

2.6 Expert clinical review and causality assessment in pharmacovigilance
2.6.1 Expert clinical review in pharmacovigilance
Since the beginning of pharmacovigilance practice (mid 1960s), expert clinical review has
been viewed as essential to assess causality during the signal evaluation process
(Agbabiaka, Savović, & Ernst, 2008; Andrews & Moore, 2014; Andrew Bate, 2003).
Detected signals are reviewed by one or more experts who are often specialists, with
expertise related to the ADR concerned (Andrews & Moore, 2014). This is referred to as
expert judgement or global introspection -- an expert expresses a judgement about possible
drug causation after having taken into account all the available and relevant information
on the considered case (Arimone et al., 2007). Expert judgment assessments are generally
expressed in terms of a qualitative probability scale (Andrews & Moore, 2014). For
example, the WHO causality categories are ‘Certain’, ‘Probable’, ‘Possible’, ‘Unlikely’,
‘Conditional/unclassified’,

and

‘Unassessable/unclassifiable’(Meyboom,

Hekster,

Egberts, Gribnau, & Edwards, 1997). During the assessment, specific structured
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approaches have been used to guide the experts from which perspective to evaluate the
possible ADR. For instance, the Swedish regulatory agency (Wiholm, 1984) recommends
the experts to assess possible ADRs from the following aspects: (1) the temporal sequence,
(2) previous information on the drug, (3) dose relationship, (4) response pattern to drug,
(5) rechallenge, (6) alternative aetiological candidates, and (7) concomitant drugs.
2.6.2 Assessment of causality
To address the assessment of causality, general principles exist that can be applied to
evaluate the causality of potential ADRs (Shakir & Layton, 2002). The theoretical basis
for these principles was proposed by Sir Austin Bradford-Hill in 1965 (Hill, 1965).
Bradford-Hill, an English epidemiologist and statistician, was the first to demonstrate that
cigarette smoking contributes toward lung cancer using what are now referred to as the
“Bradford-Hill criteria” (Richard Doll, 1994). The Bradford-Hill criteria provide
viewpoints from which to evaluate evidence indicative of causality and have been widely
used in pharmacoepidemiology. These criteria are named ‘strength’, ‘consistency’,
‘specificity’, ‘temporality’, ‘biological gradient’ (referring to dose-response relationships),
‘plausibility’, ‘coherence’, ‘experimental evidence’, and ‘analogy’ (Hill, 1965; Kleinberg
& Hripcsak, 2011; Ward, 2009). Since then, the criteria have been widely used in
epidemiology and may be applied to assess the causality of drug/ADR relationships
(Anderson & Borlak, 2011; Perrio, Voss, & Shakir, 2007; Shakir & Layton, 2002). Three
of these criteria seem particularly pertinent to the development of pharmacovigilance
methods in our study:


The strength criterion reflects that strong associations are more likely to be causal
than weak associations (Shakir & Layton, 2002). Quantitative statistical data
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mining methods evaluate ADR signals from the strength of association point of
view.


The plausibility criterion relates to evidence about mechanisms that may be
involved to support a causal relationship.



The coherence criterion relates to the consistency of the hypothesis in question with
contemporary medical knowledge.

2.7 LBD and literature NLP annotation tools
2.7.1 LBD and discovery patterns
Processing published biomedical literature to uncover implicit relationships among entities
is referred to as LBD (Bruza & Weeber, 2008; Swanson, 1986b, 1987; Weeber, Klein, de
Jong‐van den Berg, & Vos, 2001). LBD involves finding new knowledge by analyzing the
literature, rather than through scientific experimentation. This is accomplished by
identifying hidden connections between entities described in the published literature
(Swanson, 1986a, 1986b). The origins of LBD may be traced to the serendipitous discovery
that fish oils can be therapeutically useful in the treatment of Raynaud’s syndrome (poor
circulation in the peripheries) by information scientist Don Swanson (Swanson, 1986a,
1986b). Weeber et al. described the two types of LBD (Weeber et al., 2001).
One type, referred to as “open LBD”, starts from a known term or concept (generally called
A, although also referred to as C in Swanson’s early work) and tries to find an interesting
hypothesis in the form of a previously unrecognized connection to some other term. If an
article argues that A is associated with B and a second article mentions that B is associated
with C, A may treat C. For example dietary fish oil (A) affects platelet aggregation, blood
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viscosity and vascular reactivity (B), and these biological factors (B) play a role in
Raynaud's syndrome (C) (Swanson, 1986a). Consequently, it is reasonable to hypothesize
that A treats C. The open LBD process proceeds from the source term A to an unknown
target term C and culminates in the generation of a new hypothesis.
The second type of LBD is referred to as “closed LBD”. In a closed LBD process the goal
is to evaluate an existing hypothesis. Closed LBD starts with known terms A and C, with
the goal to identify intermediate terms B that provide the bridge between A and C (Weeber
et al., 2001). For example, in 1988 Swanson found intermediate concepts to explain a
hypothetical relationship between migraine and magnesium (Swanson, 1988). Smalheiser
and Swanson used closed LBD to propose an explanation for epidemiologic evidence that
estrogen might protect against Alzheimer’s disease (Smalheiser & Swanson, 1996).
LBD methodologies generally utilize statistical information derived from the frequency
with which terms, or discrete concepts extracted from the literature using automated tools
(e.g. MetaMap) or assigned to it by human annotators (Srinivasan & Rindflesch, 2002), cooccur (Hristovski et al., 2006; Yetisgen-Yildiz & Pratt, 2006). This has been referred to as
the co-occurrence model (Sehgal, Qiu, & Srinivasan, 2008). These co-occurrence statistics
are interpreted by correlation-mining and ranking algorithms (Yetisgen-Yildiz & Pratt,
2006, 2009).
A limitation of these methods is that they generally do not consider the nature of the
relationship between the terms or concepts concerned. To address this limitation,
Hristovski and his collaborators (Hristovski et al., 2006) propose using semantic relations
to eliminate spurious relationships introduced by frequently co-occurring concepts that are
not meaningfully related. In their initial work, the semantic relations concerned were
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extracted from the literature by two NLP systems: SemRep (Rindflesch & Fiszman, 2003)
and (specifically to extract phenotypic information) BioMedLEE (L. Chen & Friedman,
2004). Their approach involved the specification of “discovery patterns”, patterns of
relationships between concepts that may indicate an implicit therapeutic relationship
(Hristovski, Friedman, Rindflesch, & Peterlin, 2008). These conditions can be specified as
sets of semantic predicates. For example, Ahlers et al. (Ahlers, Hristovski, et al., 2007)
defined the May_Disrupt pattern as follows:
Substance X <inhibits> Substance Y
Substance Y <causes|predisposes|associated with> Pathology Z
Substance X <may disrupt> Pathology Z
Variants of this approach have been applied to generate or support the hypotheses that fish
oil treats Raynaud’s disease (Hristovski et al., 2006), insulin treats Huntington disease
(Hristovski et al., 2006), and antipsychotic agents prevent cancer (Ahlers, Hristovski, et
al., 2007). Recently, this approach was also adapted to provide evidence to support the
plausibility of an observed drug/ADR association (Hristovski et al., 2012a; Hristovski,
Burgun-Parenthoine, Avillach, & Rindflesch, 2012b), providing proof-of-concept that
LBD methods can be applied within the problem domain of pharmacovigilance. Regardless
of the application domain, knowledge used to populate discovery patterns is extracted from
the biomedical literature using NLP.
2.7.2 Literature NLP annotation tools
MetaMap and SemRep are two examples of tools that have been used to extract information
encoded in the biomedical literature. MetaMap is a widely-used NLP tool that identifies
concepts from the Unified Medical Language System (UMLS) in biomedical text (A. R.
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Aronson & Lang, 2010; A. R. Aronson, 2001). SemRep (Rindflesch, Fiszman, & Libbus,
2005; Rindflesch & Fiszman, 2003) is a rule-based NLP tool (A. R. Aronson & Rindflesch,
1998) that draws on concepts extracted by MetaMap and medical domain knowledge in the
UMLS to extract semantic predications (Rindflesch & Fiszman, 2003). Its input consists
of sentences from the literature; its output is a series of semantic predications identified in
the respective text. A semantic predication is a subject-predicate-object triple sentence in
which the subject and object are UMLS concepts and the predicate is a semantic
relationship. For example, metformin (UMLS Concept C0025598) TREATS diabetes
mellitus (C0011849) is a semantic predication extracted from the phrase “Treatment of
diabetes mellitus with metformin”. Evaluations of SemRep reveal a precision between 0.73
and 0.81, and a recall of 0.55 on the biomedical literature (A. R. Aronson & Rindflesch,
1998; Kilicoglu, Fiszman, Rosemblat, Marimpietri, & Rindflesch, 2010; Rindflesch &
Aronson, 2002). Semantic predications benefit the LBD process in several respects. The
additional information provided by semantic predications makes the LBD results easier to
interpret. In addition, it has been noted that a large number of uninformative co-occurrences
must be manually reviewed when LBD is based on lexical statistics alone (Lindsay &
Gordon, 1999). In contrast, semantic predications provide the means to isolate relationships
between concepts that are logically connected in a meaningful way.

2.8 Semantic Vectors (Cohen & Widdows, 2009)
Regardless of whether co-occurrence relations or discovery patterns are used, LBD systems
must explore large numbers of co-occurring terms or possible reasoning pathways to
identify explanatory hypotheses (for closed discovery) or previously unrecognized
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relationships (for open discovery). Consequently, the process of LBD can be
computationally expensive, and thus faces scalability issues in the context of the rapid
growth of the biomedical literature. In contrast, the field of distributional semantics has
produced corpus-derived statistical models that can measure the relatedness between two
concepts by comparing vector representations of these concepts, called semantic vectors,
that are derived from the contexts they have occurred in (Cohen & Widdows, 2009),
without the need to explicitly explore co-occurring concepts once the initial model has been
generated. Consequently, several authors have explored the use of distributional models
for LBD (Cohen et al., 2010; Cole & Bruza, 2005; Gordon & Dumais, 1998).
2.8.1 Overview of semantic vectors
These geometrically motivated models of distributional semantics represent terms or
concepts as high-dimensional vectors derived from the contexts in which they have
occurred. Relatedness between a pair of terms or concepts is then estimated from their
representing vectors’ similarity (Cohen et al., 2010). The vector components can be binary,
ternary, real, or complex values (Kanerva, 2009; Widdows & Cohen, 2012).
The overall methodology of semantic vectors is to build vector representations for terms
and documents. Different methods exist to compute these vectors. For example, document
vectors can be built from term-by-context matrices (Cohen & Widdows, 2009); in Latent
Semantic Analysis (LSA) the initial representation is a term-document matrix derived from
a corpus (Landauer & Dumais, 1997).
Overall, document vectors are derived from the vector representations of the terms that
they contain and as a consequence, documents with similar terms have similar vector
representations. A mathematically computed distance between vectors is then
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representative of the similarity of the documents they represent. A key aspect is that the
abstract concept of meaning or semantics of a concept is converted into a metric that can
be computationally exploited.
Term-by-context matrices or term-document matrices can be large for text corpora with a
high number of terms and documents. PubMed/MEDLINE for example has both dozens of
millions of terms and documents. Deriving vector representations with term-by-context or
term-document matrices can thus become computationally unfeasible. Methods to
circumvent this problem by reducing the vector dimensionality have been conceived and
shown to effectively preserve the meaning of the represented concepts as described in the
next section.
2.8.2 Scalability and random indexing (RI)
RI, a relatively recent development for dimension reduction, supports the derivation of
semantic distance from large corpora at minimal computational expense (Cohen &
Widdows, 2009). RI further improves the scalability of distributional methods by avoiding
computationally intensive approaches to dimension reduction of the original term-bycontext matrix (Kanerva, Kristofersson, & Holst, 2000; Kanerva, 2010). The algorithm’s
computational complexity scales linearly with increasing size of the input data. It can be
incrementally updated as new documents are added without retraining the whole dataset;
thus it is applicable to large corpora such as MEDLINE. Two variants of RI have been
applied to LBD in our previous work, which can efficiently infer and identify therapeutic
relationships. One is Reflective Random Indexing (RRI) (Cohen et al., 2010), which
models co-occurrence. The other one is Predication-based Semantic Indexing (PSI)
(Cohen, Widdows, Schvaneveldt, Davies, et al., 2012), which implements discovery
32

patterns in vector space. On account of their scalability, these models permit inference on
a scale that would be prohibitively time-consuming if explicit exploration of all possible
reasoning pathways were attempted. This is accomplished through a mechanism known as
“indirect inference” (Landauer & Dumais, 1997), which enables distributional models to
find meaningful connections between terms that do not co-occur with one another directly,
without the need to explore intervening terms explicitly. Further details about these two
LBD distributional semantics models (RRI and PSI) are provided in Section 4.2.1 and 4.2.2
respectively.

2.9 Research opportunities
2.9.1 Active drug surveillance with EHR
With the broader availability of EHR data and the building of data repositories by
integrating different EHR systems (FDA Science Board Subcommittee, 2011; P. Lopes et
al., 2013; Platt et al., 2009; Stang et al., 2010), an active and real time pharmacovigilance
surveillance may be achieved in the near future. This poses informatics challenges from
the data integration perspective. With respect to EHR signal detection, the challenge of
improving signal detection is likely to be a research focus. This can be achieved using
statistical data mining methods, and by improving the accuracy of true drug/ADR cooccurrence data using informatics methods.
2.9.2 Using distributional semantic models to find plausible drug/ADR associations
Signal evaluation is still a key pharmacovigilance challenge (P. Lopes et al., 2013). The
proposal of substantiating and verifying ADR signals by analyzing the literature and
existing drug-related knowledge bases in an automated fashion raises many research
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questions. With the scalability of newer distributional semantics methods, and their
capability of modeling the indirect relationships between entities using literature, I posit
that LBD distributional semantics can retrieve evidence from the literature to establish the
plausibility of connections between drugs and ADRs. This will assist the
pharmacovigilance evaluation process by providing relevant evidence for domain experts
to consider for causality assessment in signal evaluation.

In the chapters that follow, I will evaluate this hypothesis by using state-of-the-art
statistical algorithms to analyze an EHR system and identify statistically significant
drug/ADR associations. Scalable LBD models based on distributional semantics are
designed and built to leverage knowledge from the biomedical literature to identify
plausible drug/ADR associations. An evaluation is conducted to determine the validity of
each developed method.
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Chapter 3: Signal Detection from Outpatient Electronic Health Record Data Using
Statistical Mining
Research suggests data collected by SRS are limited by long time latency, incorrect or
incomplete clinical information, underreporting and reporting bias (Alvarez-Requejo et al.,
1998; Hasford et al., 2002). Clinicians and researchers have also utilized existing
healthcare data sources such as Electronic Health Records (EHR) to attempt to identify
previously unreported adverse drug reactions (ADRs) (Haerian et al., 2012; Harpaz et al.,
2013; Trifirò et al., 2009; Wang et al., 2009). However, these data are inherently noisy as
drugs and potential side effects may co-occur in the EHR for many reasons. In addition,
the EHR often contains free-text data, and the accuracy of Natural Language Processing
(NLP) tools is not perfect. New methods are required to selectively identify potentially
hazardous drug/ADR associations. Consequently, the development of computational
approaches to more accurately detect potential side effects is currently an active area of
research (Bauer-Mehren et al., 2012; Deftereos et al., 2011; Friedman, 2009; Oliveira et
al., 2013; Shetty & Dalal, 2011). These approaches have predominantly focused on
improving signal detection using statistical methods, machine learning or some
combination thereof.
Statistical methods employed mostly involve disproportionality analysis. Other statistical
algorithm based on co-occurrence has also been explored to detect possible side effects
from unstructured clinical notes. Both statistical methods are based on an independence
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model (Wang et al., 2009; Zorych et al., 2011). Disproportionality measure was developed
from SRS data and has been tested to be able to retrieve drug/ADR associations from EHR
data (Liu, McPeek Hinz, et al., 2012; Zorych et al., 2011) under the premise that the
observed co-occurrence of a drug and an event can be considered as the reported a possible
drug/ADR association (Zorych et al., 2011). Other statistical algorithm based on cooccurrence, originated from detecting the above-chance frequent occurrence of two entities
from a text corpus, has also been demonstrated to be effective in retrieving possible
drug/ADR associations from clinical corpus (discharge summaries in (Wang et al., 2009)).
The motivation of using this algorithm is based on the hypothesis that a drug entity and a
possible problem entity are more likely to appear together than random combinations of
any drug entity and any problem entity (Cao et al., 2007; Wang et al., 2009).
However, EHR data was not captured for the purpose of reporting side effects, and
consequently there exists information other than drug related problems, e.g. drug treatment
information (symptoms, indication, etc.). So researchers need to select a related cohort for
investigating ADRs using EHR data. Liu et al. (Liu, McPeek Hinz, et al., 2012) selected
drugs and corresponding abnormal laboratory results as possible side effects from
inpatients structured clinical data as the cohort. Wang et al. (Wang et al., 2009) utilized a
NLP tool to process unstructured clinical notes and only selected drug and possible side
effects related to the processed sections as the cohort. Consequently, statistical methods
and machine learning tools are utilized together to analyze unstructured clinical notes for
finding possible drug/ADR associations.
Structured (Liu, McPeek Hinz, et al., 2012) and unstructured (Wang et al., 2009) inpatient
EHR data and structured outpatient (Honigman, Light, Pulling, & Bates, 2001; Honigman,
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Lee, et al., 2001) EHR data have been demonstrated to be a possible data source to identify
ADRs. However, to our knowledge, unstructured outpatient EHR data hasn’t been used for
ADRs identification. OMOP preliminary results suggest that the performance of using
EHR systems varies by data source (FDA Science Board Subcommittee, 2011). In this
study, an unstructured outpatient EHR data is evaluated to be a feasible data source for
detecting ADRs. Both disproportionality measures and other statistical algorithm based on
co-occurrence are used to analyze the outpatient EHR data and find possible drug/ADR
associations. Corresponding workflow is discussed.

3.1 Materials
3.1.1 Clinical data warehouse (CDW)
The CDW was developed by the Center for Clinical and Translational Science (CCTS) at
the University of Texas Health Science Center at Houston. The outpatient EHR system for
UT Physicians (Allscripts), is hosted on CDW for clinical research usage. It contains
medical records on approximately 364,000 patients treated by UT Physicians (Saitwal et
al., 2012). The batch used in this experiment is 20130130 containing about ten-year clinical
data until January, 2013 and 2,603,279 outpatient clinical notes. This large sample size
provided by the EHR system may provide enough power to detect small frequency ADRs.
This work is qualified for an IRB exemption and has been approved by the Committee for
the Protection of Human Subjects. This project refers to HSC-SBMI-12-0226 – “Detection
of adverse drug events from electronic health records”.
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3.1.2 Medical language extraction and encoding system (MedLEE)
MedLEE is a NLP system, designed to parse narrative patient reports into structured
representations including UMLS codes for identified concepts (Friedman, Shagina,
Lussier, & Hripcsak, 2004). Friedman et al (Friedman et al., 2004) report the recall of
MedLee for UMLS coding of all terms from 150 randomly selected sentences -- selected
from a text collection consisted of 818,000 sentences that were retrieved from de-identified
patients’ discharge summaries -- as 0.77 compared with a reference standard which was
determined by seven experts’ manual review. The precision of the system was reported as
89% for encoding a second set of 150 randomly selected sentences from the text collection
then subsequently validated by experts. Since the overall evaluation was conducted on the
records from the same institution in which the NLP system was developed, performance
may be lower elsewhere as NLP systems often must be adapted to new contexts.
3.1.3 Side effect resource 2 (SIDER2 (Kuhn, Campillos, Letunic, Jensen, & Bork,
2010))
SIDER2 is a publicly available database containing information on marketed medicines
and their known adverse reactions (Kuhn et al., 2010). SIDER2 was used to construct a
dataset for our experiment and as a reference standard to confirm whether a predicted side
effect is a true adverse reaction. SIDER2 contains 996 drugs, 4,192 side effects, and 99,423
drug/ADR pairs. Only those side effects and drugs that were contained in the EHR data
were retained, leaving a total of 833 drugs, 2123 side effects, and 71,753 drug/ADR pairs.
3.1.4 Hierarchical relationships between concepts from UMLS knowledge base
The number of clinical notes for a problem was extended by grouping related concepts
based on the UMLS semantic network and UMLS Metathesaurus, specifically the
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MRREL.RRF ﬁle (U. S. National Library of Medicine, 2009). This file includes
relationships between UMLS concepts found in the UMLS Metathesaurus, while the
relationship can be synonym (SY), child (CHD), sibling (SIB), parent (PAR) and etc. By
utilizing these ancestor-oﬀspring hierarchical relationships (Figure 3-1), all oﬀspring nodes
for a SIDER2 ADR can be retrieved and subsequently are considered as related concepts,
and their corresponding clinical notes are counted for the SIDER2 ADR. Take Breast
Carcinoma as an example, Breast Carcinoma (C0678222) is a parent node of Mucinous
Carcinoma of Breast (C1334807) and Lobular Carcinoma (C0206692), and a child node of
Carcinoma (C0007097). This hierarchical relatedness can be used to group related concepts
for Breast Carcinoma and consequently to count its clinical notes.

Figure 3-1: The example ancestor-offspring hierarchy relationships between UMLS
concepts

3.1.5 MEDication-Indication (MEDI)
It was anticipated that co-occurring drugs and problems in the clinical notes might often
be related therapeutically. Consequently, I evaluated the utility of an indication knowledge
resource, MEDI (Wei et al., 2013), as a means to eliminate drug indications from
consideration as potential side effects. MEDI is a medication indication resource that was
extracted from a set of commonly used medication resources, including RxNorm,
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MedlinePlus, SIDER2, and Wikipedia (Wei et al., 2013). MEDI drugs are represented by
RxNorm codes, and indications are represented by ICD-9 codes. MEDI contains 3112
medications and 63,343 medication-indication pairs (MEDI-Complete). Additionally, the
MEDI high-precision subset (MEDI-HPS) was also created by only including indications
that are retrieved from RxNorm or at least two of the three other resources. MEDI-HPS
contains 2136 medications and 13,304 medication-indication pairs. The estimated
precision of MEDI-HPS is about 92%.

3.2 Methods
3.2.1 Annotating the EHR data using MedLEE
Drugs and co-occurring problems from medical records in the CDW were annotated by
MedLEE. The medical records I utilized are free-text, unstructured clinical encounter
documentations in outpatient setting. Each clinical summary was processed by MedLEE,
resulting in an output that included UMLS-codes and semantic types for each extracted
concept. Concepts denoted as a “medication” or “problem” were utilized as the source of
potential side effects. Their occurrence at document level was recorded, to enable
evaluation of the frequency with which a drug or a problem occurred in the EHR data.
3.2.2 Construct test data set
All SIDER2 drugs and side effects that are contained in the EHR data were utilized for the
experiment. All selected drugs and ADRs are paired up to construct a SIDER2 drug/ADR
test set. This resulted in a set of 1,768,459 drug/ADR relationships, 71,753 of which were
true and 1,696,706 of which were false.
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3.2.3 Retrieve co-occurrence data for SIDER2 test set
Co-occurrence data for the SIDER2 drug/ADR test set were retrieved from the EHR system
and is referred to as original co-occurrence data. By using the ancestor-offspring
hierarchical relationships in UMLS knowledge base, for each SIDER2 ADR, the EHR
clinical documents that contain this concept or this concept’s all related offspring concepts
are considered as ADR positive reports. This may also improve statistical power since the
prevalence of some side effects is relatively low. By doing so, a second set of co-occurrence
data were retrieved for each SIDER2 drug/ADR test set and is referred to as descendent
co-occurrence data.
3.2.4 Statistical algorithms
3.2.4.1 Disproportionality analysis
After retrieving co-occurrence data for the drugs and ADRs that appear in the test set, a
contingency table was constructed for each drug-problem pair. Disproportionality
measures – reporting odds ratio (ROR), proportional reporting ratio (PRR), Yule’s Q
(Yule), information component (IC), Multi-item gamma Poisson Shrinker (MGPS) -- were
applied to identify statistically significant drug/ADR pairs (Table 2-1 in Chapter 2). If the
observed occurrence / expected occurrence is more than a quantitative threshold (which
varies across different disproportionality measures), the drug/ADR combination is
considered as a signal.
3.2.4.2 Other statistical algorithm based on co-occurrence
To test independence, Chi-squared test can be applied to drugs and problem-related entities
extracted from the EHR data using NLP (or structured data if available) to test the strength
of the relationship between drugs and problems based on their paired and independent
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observations in the dataset. There may exist interrelations between different drugs and
different problems.
The Chi-squared value reflects the magnitude of the dependence. However, traditional Chisquared statistics rejects most null hypotheses due to the large sample size (Cao et al.,
2007) which results in false positives. Zorych et al. (Zorych et al., 2011) has shown that
there are large amount of false positive signals detected from EHR data. In Chi-squared
test, each drug/ADR pair is tested separately without taking into account the multiple
comparison. Multiple comparison refers that multiple drug/ADR associations hypotheses
are tested from the same dataset simultaneously (Ahmed, Dalmasso, et al., 2010).
Researchers have proposed statistical approaches to control error rates in multiple
hypothesis testing. Among these, the false discovery rate (FDR) was introduced to measure
the multiple-hypothesis testing error and has been successfully used in large-scale genomic
studies to control false positive results (Benjamini & Hochberg, 1995; J. D. Storey &
Tibshirani, 2003; J. D. Storey, 2002). FDR avoids the over-conservativeness of the
standard Bonferroni approach to multiple hypothesis testing, and has proven to be powerful
in identifying sparse signals from a large number of tests (Cai & Sun, 2009). For example,
FDR is used to detect differential gene expression in replicated DNA microarray
experiments, where unknown dependencies are likely to occur (J. Storey & Tibshirani,
2001). On account of the proven utility of the FDR approach as a means to identify sparse
signals from large datasets (Ahmed, Thiessard, Miremont-Salamé, Bégaud, & TubertBitter, 2010), I also used the Chi-squared test augmented with the FDR as measuring
significance threshold. The FDR approach (J. D. Storey & Tibshirani, 2003) determines
the statistical significance of a q value for each tested pair. q values are estimated from p
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values, which measure significance in terms of the false positive rate. The false positive
rate is the rate at which null hypotheses are rejected (false drug/ADR associations are
predicted as positive by a statistical model). For example, a false positive rate of 5% means
that on average 5% of the false drug/ADR associations will be predicted as positive by the
statistical model. The q value measures significance in terms of false discovery rate, the
rate at which statistically significant signals are, in fact, false drug/ADR associations. Table
3-1 describes how overall accuracy or error is measured in m drug/ADR pairs testing.

Table 3-1: Overall error measure in FDR approach (J. D. Storey & Tibshirani, 2003)
Tested
Tested not
Total
significant
significant
(Positive)
(Negative)
Null hypothesis is True
False Positive
True Negative
m0 (FP+TN)
(no relationship between drug (FP)
(TN)
(# of true null
and ADR)
α (Type I
drug/ADR pairs)
error)
Alternative hypothesis is True True Positive
False Negative
m1 (TP+FN)
(has relationship between drug (TP)
(FN)
(# of true alternative
and ADR)
β (Type II error) pairs)
Total
S = 1 (FP+TP) S = 0
m (m0+m1 || S=1 +
(# of pairs
S=0)
tested
(total drug/ADR
significant)
comparisons)
𝐹
] ≤ 0.05
𝑚0
𝐹
𝐹
𝑓𝑎𝑙𝑠𝑒 𝑑𝑖𝑠𝑐𝑜𝑣𝑒𝑟𝑦 𝑟𝑎𝑡𝑒 (𝐹𝐷𝑅) = 𝐸[ ] = 𝐸[
] ≤ 0.05
𝑆
𝐹+𝑇
𝑚0 − 𝐹
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =
𝑚0
𝑇
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑚1
𝑚0 ∙ (1 − 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦)
𝑓𝑎𝑙𝑠𝑒 𝑑𝑖𝑠𝑐𝑜𝑣𝑒𝑟𝑦 𝑟𝑎𝑡𝑒 (𝐹𝐷𝑅) = 𝐸[
]
𝑚0 ∙ (1 − 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦) + 𝑚1 ∙ 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑟𝑎𝑡𝑒 = 𝐸[
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3.2.5 Filtering indications
To evaluate the utility of existing knowledge of indication, the two MEDI lists were applied
to exclude indication relationships from the false pairs and tested using the top 5 best
performing statistical models using the original SIDER2 test set.

3.2.6 Performance evaluation
The performance for different statistical algorithms were calculated and compared using
the original SIDRE2 test set. The best five performing models were advanced for testing
with different MEDI interventions and procedures to group related concepts.

3.3 Experimental design
The CDW EHR clinical narratives were processed and annotated by MedLEE (Friedman
et al., 2004) with default setting. MedLEE extracts biomedical concepts from the EHR and
categorizes these into semantic types based on large lexicon. Within MedLEE’s annotated
output, those entities labels as “medication” and “problem” were considered as candidate
drugs and ADRs respectively. SIDER2 (Kuhn et al., 2013) was used to construct a
drug/ADR reference standard (SIDER2 drug/ADR test set) by pairing up all drugs and
ADRs that exist in both the EHR data and SIDER2 to generate a set of 71,753 true and
1,696,706 false drug/ADR relationships. Since SIDER2 was extracted from package
inserts by text mining tools, there may exist false drug/ADR associations because of the
text mining error or over reporting of side effects (Duke J, Friedlin J, & Ryan P, 2011).
Existing disproportionality measures and Chi-squared test with FDR for detecting
drug/ADR associations from outpatient clinical notes were calculated and compared. In
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this experiment, different thresholds (4, 6, 10, 25) of co-occurred drug/ADR reports were
considered as the second condition to predict true drug/ADR associations.
Clinical narratives may have different concepts representing a SIDER2 ADR. Clinical
notes containing these related concepts can be retrieved to expand the examples available
for each SIDER2 ADR. In addition, a co-occurring drugs and problems may indicate
therapeutic relationships, the MEDI lists were used to filter drug indication relationships
from drug/problem candidates. Overall, my experiments concerned three methodological
variants: (1) the choice of statistical measure; (2) increasing the examples available for
each potential ADR by grouping related concepts for a SIDER2 problem; and (3) filtering
known indication relationships.

3.4 Results
3.4.1 Experiment dataset
There are 2,603,279 clinical narratives (narrative notes in CDW updates to 01/30/2013)
that were annotated by MedLEE. 2,325,614 notes that contain at least medication or
problem were used for the experiment. There are 229 narrative types in this batch. 23.5%
of the notes are labeled as “chart note” (Table 3-2). A chart note, also called as a progress
note, is dedicated when an established patient is seen for a repeat visit.
In the EHR system, there are 7780 drugs and 10,670 problems. For SIDER2 set, there are
833 SIDER2 drugs that are also contained in the CDW, and 2123 SIDER2 side effects that
are contained in the CDW. These overlapping drugs and problems between SIDER2 and
CDW were used to build an evaluation set for the experiment. In this evaluation set, all
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drugs were paired up with all problems. The true drug/ADR pairs are the pairs that are exist
in SIDER2. The false drug/ADR pairs are the pairs that do not exist in SIDER2.

Table 3-2: Top 10 clinical documentation types in the EHR system
clinical documentation Number of narrative Percentage of total
type
notes
clinical notes
Chart Note
546,025
0.235
Clinical Note
180,192
0.077
Clinical Summary144,486
0.062
RTF
Pre-Live Dictation.
120,295
0.052
Telephone Note
118,701
0.051
Nurse Note
113,253
0.049
Est Patient
96,567
0.041
Established
81,496
0.035
New Patient
63,110
0.027
UT Imaging.
60,419
0.026

3.4.2 Query the co-occurrence data for experiment datasets
For the drug/ADR pair in the evaluation set, the number of notes that contain the drug-ofinterest and ADR-of-interest were counted to quantify co-occurrence. As discussed
previously, to improve the statistical power, the notes that contain related problems-ofinterest were also considered relevant notes when estimating the drug-problem cooccurrence counts for this problem (so any drugs co-occurring with a taxonomically related
problem would be counted as though they had co-occurred with the index problem). On
account of the two options for measuring associations with respect to related problems,
there are two contingency tables for each experiment set (original vs. descendent cooccurrence).
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3.4.3 Statistical results
3.4.3.1 Performance results
3.4.3.1.1 Performance of statistical algorithms with original co-occurrence data
The performance of predicting true positives, precision, recall and F-measure for different
statistical algorithms with different co-occurrence threshold are compared and plotted in
Figure 3-2. The average precision is 0.1315±0.0105. From this, I can anticipate that 1015% of recovered signals from outpatient clinical notes can be true side effects. Chisquared statistics with FDR threshold is the besting performing model with an F-measure
of 0.1826. The best 5 performing statistical models based on F-measure are used in the
following analysis.
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Figure 3-2: Comparison of ability of different performance metrics (R-ROR, P-PRR, YYule, C-Chi-square, F-Chi-square with FDR, M-MGPS) to recover SIDER2 side effects
for different statistical algorithms with different drug/ADR co-occurrence threshold; top
left, top right, bottom left, and bottom right are the comparison of number of true
positives, precision, recall, and F-measure, respectively

3.4.3.1.2 Effects of potential ontology intervention
The best 5 performing statistical models from previous results were used in comparing
their performance between original and descendant co-occurrence data (Figure 3-3). With
the descendant co-occurrence data, the algorithms detect more true positives, but this was
counter-effected by more false positives retrieved and leads to the decreased precision.
Overall, the F-measure decreases with the descendant co-occurrence data (Figure 3-4).

48

Figure 3-3: Comparison of the predicted drug/ADR association count comparing between
original and descendant co-occurrence set for best five performing statistical models (F2Chi-square with FDR and 25 co-occurrence; C-Chi-square with 25 co-occurrence; F1- Chisquare with FDR and 10 co-occurrence; P-PRR with 10 co-occurrence; Y-Yule with 10 cooccurrence); top left, top right, bottom left, and bottom right are the comparison of number
of true positives, false positives, true negatives, and false negatives, respectively
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Figure 3-4: Comparison of ability of different performance metrics to recover SIDER2
side effects for best five performing statistical algorithms (F2-Chi-square with FDR and 25
co-occurrence; C-Chi-square with 25 co-occurrence; F1- Chi-square with FDR and 10 cooccurrence; P-PRR with 10 co-occurrence; Y-Yule with 10 co-occurrence); top left, top
right and bottom are the comparison of precision, recall, and F-measure, respectively

3.4.3.1.3 Effects of MEDI intervention
In this test, I selected the five statistical models with the best F-measure and evaluated the
effects of different MEDI interventions. Since I excluded indications from false pairs in
the reference standard (Table 3-3), it is expected that this will decrease the number of false
positives (consequently increasing the true negatives). However, the number of true
positives will not be changed, so recall should not be changed either. The precision may be
improved because of the decreasing of false positives, as may the F-measure. The results
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of these experiments are shown in Figure 3-5 and 3-6 below, which present the filtering
the indications can decrease the predicted false positives and correspondingly increase the
precision and F-measure.

Table 3-3: Number of false pairs that have been excluded as indications
Reference Set
true pairs
false pairs
Total pairs
Without filtering out indications
71,753
1,696,706
1,768,459
Filtering indication by MEDI-HPS
71,753
1,694,739
1,766,492
Filtering indication by MEDI71,753
1,690,353
1,762,106
Complete

Figure 3-5: Comparison of the predicted drug/ADR association count with different
MEDI filtering indications for best five performing statistical models (F2-Chi-square
with FDR and 25 co-occurrence; C-Chi-square with 25 co-occurrence; F1- Chi-square
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with FDR and 10 co-occurrence; P-PRR with 10 co-occurrence; Y-Yule with 10 cooccurrence); top left, top right, bottom left, and bottom right are the comparison of
number of true positives, false positives, true negatives, and false negatives, respectively

Figure 3-6: Comparison of ability of different performance metrics to recover SIDER2
side effects for best 5 performing statistical algorithms (F2-Chi-square with FDR and 25
co-occurrence; C-Chi-square with 25 co-occurrence; F1- Chi-square with FDR and 10
co-occurrence; P-PRR with 10 co-occurrence; Y-Yule with 10 co-occurrence) after
filtering indications by different MEDI lists; top left, top right and bottom are the
comparison of precision, recall, and F-measure, respectively

3.5 Discussion
This experiment demonstrated that unstructured outpatient data can be used as a data source
for detecting drug/ADR associations. The statistical testing procedure is well established
for signal detection and can be potentially improved by considering the error controlling
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within multiple comparison setting. Filtering known therapeutic relationships from
possible drug/ADR candidates can improve the overall performance; this should become a
required component in pharmacovigilance using EHR data.
This work has several limitations. MedLEE was used to extract medications and problems
from the CDW EHR system. After reviewing the annotated problems, there were some
unlikely problem terms such as “arms” or “legs”. These are less likely problems related to
medications and maybe caused by NLP processing errors. Since the procedure is not tied
to a specific NLP tool, there is also the possibility of selecting another NLP tool with better
performance. With the improvement of NLP technology, this method should get better
performance accordingly.
There is no agreed-upon gold standard in the field of pharmacovigilance (Tatonetti et al.,
2012), and it has been pointed out that SIDER2 data set may contain false drug/ADR
associations (Duke J et al., 2011). This is likely to affect the performance evaluation by
including wrong validation data. In addition, SIDER doesn’t include all the drugs that were
used in the EHR system. Possible causes include the usage of different drug names, new
drugs being used in clinical practice and terminology mapping or NLP annotation errors.
This further hints at the fact that a comprehensive and accurate reference set is needed for
accurately evaluating pharmacovigilance systems or methods.
By exploiting UMLS hierarchical relationships, sub-concepts for a SIDER problem can be
grouped together and the pathways between those sub-concepts can be used to relate to the
comprising SDIER2 problem concept. However, initial experiments didn’t show an
improvement of the overall performance in the experiment. This does not however
necessarily imply that grouping related concepts isn’t suitable for improving the signal
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detection performance. To assess this better, future studies are needed to scrutinize the
effects of subsumption and grouping of concepts that are related through a hierarchy.
Ontological inference experiments should be used to group related concepts in a more
controlled and accurate manner to determine the effects on signal detection performance.

3.6 Conclusion
Drug/ADR signals can be detected from the outpatient unstructured EHR data with existing
disproportionality measures and Chi-square statistics with FDR. Filtering known
therapeutic relationships from possible drug/ADR combinations can exclude confounding
factors and improve the performance. With the precision of about 10-15% of evaluated
SIDER2 by statistical algorithms, additional signal evaluation is needed for the detected
drug/ADR signals.
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Chapter 4: Using Knowledge Extracted from the Literature to Identify Plausible
Adverse Drug Reactions1
Over the last decade, drug safety data obtained from spontaneous reporting systems (SRSs)
have been analyzed using quantitative data mining procedures to retrieve strongly
associated drug/ADR pairs (Puijenbroek et al., 2003; Rawlins, 1988a, 1988b). These
highlighted associations are subsequently reviewed and scrutinized by domain experts.
Review by domain experts is required to evaluate a signal using their knowledge and
judgment to find a signal with clinical significance. However, on account of the humanintensive nature of this task, automated assistance is desirable. In this study, I attempt to
partially automate this aspect of the signal evaluation process. I do so using methods that
leverage knowledge extracted from the biomedical literature as a means to assess the
plausibility of an observed drug/ADR association.

4.1 Materials
In this study, MetaMapped Medline Baseline (MMB) and Semantic MEDLINE Database
(SemMedDB) were used to represent knowledge from the biomedical literature. Side
Effect Resource 2 (SIDER2) was used as data set for drug/ADR associations. The Semantic
Vectors package was used to build concept-based (RRI, Reflective Random Indexing) and

1

This chapter is published at: Shang, N., Xu, H., Rindflesch, T. C., & Cohen, T. (2014). Identifying
plausible adverse drug reactions using knowledge extracted from the literature. Journal of Biomedical
Informatics.

55

predication-based (PSI, Predication-based Semantic Indexing) semantic space models
(Cohen et al., 2010; Cohen, Widdows, Schvaneveldt, Davies, et al., 2012).
4.1.1 MMB and SemMedDB
2012 MMB was used as a repository for concept-based modeling. The MMB contains
20,494,848 articles included in Medline up to November, 2011 and contains 399,701
distinct concepts. The SemMedDB V2.2 (semmedVER22) was used for predication
modeling, which was processed with SemRep version 1.5. This was the current version
when the experiments started. SemMedDB contains 22,252,812 citations included in
Medline up to March 31, 2013 and contains 63,795,467 predications. There are 58 distinct
predicates and 257,350 distinct concepts in SemMedDB. There are also negated
predications in the SemMedDB repository (e.g. anticoagulant_therapy NEG_TREATS
(does not TREAT) phlebitis). However, the number of negative predications is relatively
small (1.2% of total predications) and consequently they were not included in the PSI
model.
4.1.2 SIDER2
SIDER2 is a publicly available database containing information on marketed medicines
and their known adverse reactions (Kuhn et al., 2010). SIDER2 was used to construct a
dataset for the experiment and as a reference standard to confirm whether a predicted side
effect is a true adverse reaction. SIDER2 terms were normalized by mapping drug and side
effects terms to UMLS CUI with UMLS Terminology Services (UTS) API 2.0 (U.S.
National Library of Medicine & National Institutes of Health, 2012). These UMLS CUIs
were then subsequently searched in SemMedDB and MMB to retrieve the mapped UMLS
concepts which are represented in SemMedDB and MMB.
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SIDER2 contains 996 drugs, 4,192 side effects, and 99,423 drug/ADR pairs. Only those
side effects and drugs that were represented in both the RRI and the PSI spaces were
retained, so the reference set contains 959 drugs, 3,436 side effects, and 90,787 drug/ADR
pairs. Each vector model’s search space was composed of vectors representing the SIDER2
side effects. For the PSI model, SIDER2 drug/ADR pairs were also used as training data
to infer predicate reasoning pathways.
4.1.3 MEDication-Indication (MEDI)
As I would anticipate connections in the literature between medications and diseases they
treat, I evaluated the utility of another knowledge resource, MEDI (Wei et al., 2013), as a
means to eliminate drug indications from consideration as potential side effects. MEDI is
a medication indication resource that was extracted from a set of commonly used
medication resources, including RxNorm, MedlinePlus, SIDER2, and Wikipedia (Wei et
al., 2013). MEDI drugs are represented by RxNorm codes, and indications are represented
by ICD-9 codes. MEDI contains 3,112 medications and 63,343 medication-indication
pairs. Additionally, the MEDI high-precision subset (MEDI-HPS) was created by only
including indications that are retrieved from RxNorm or at least two of the three other
resources. MEDI-HPS contains 2,136 medications and 13,304 medication-indication pairs.
The estimated precision of MEDI-HPS is about 92% (Wei et al., 2013).
In the experiments, MEDI was used to eliminate drugs’ indications from the side effects
search space. To do so, all terms representing drugs (RxCUI) and indications (ICD-9 codes)
in MEDI were normalized to UMLS concepts, and then each drug’s indications were
filtered from this drug’s search space. In many cases, there exist hierarchical relationships
between concepts. For example, C0264702 acute myocardial infarction of apical-lateral
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wall is a child node of C0155626 acute myocardial infarction. So in the experiments, I
extended the MEDI list by aggregating the related concepts by different hierarchical
relations. I tested these various extensions of the MEDI list as different MEDI
interventions.

4.2 Methods
4.2.1 RRI
RRI (Cohen et al., 2010) is a variant of RI adapted to enable the recognition of meaningful
indirect associations. The variant of RRI I used for the experiments allows for the
estimation of semantic relatedness between UMLS concepts, and proceeds as follows.
First, all terms in the text corpus are assigned unique vector representations, known as
elemental vectors. I will refer to the elemental vector for concept C as E(C) for the
remainder of this manuscript. In accordance with the RI paradigm (Kanerva, 2009),
elemental vectors are generated stochastically. In this way, RI creates unique fingerprints
for all terms in the text corpus. The vector components can be binary, ternary, real, or
complex values (Kanerva, 2009; Widdows & Cohen, 2012). In the experiments, I use
32,000 dimensional binary vectors constructed in accordance with the Binary Spatter Code
(BSC) (Kanerva, 1994), one of a family of representational approaches known as Vector
Symbolic Architectures (VSAs) (Gayler, 2004; Kanerva, 1994, 1996; Plate, 1995). This
dimensionality was selected based on the results of simulation experiments in previous
research (Wahle, Widdows, Herskovic, Bernstam, & Cohen, 2012), which suggest that at
this dimensionality around 2,000 unique elemental vectors can be superposed with low
probability of the superposed product being closer to some other elemental vector in the
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space than its component vectors. However, I did not attempt to optimize this parameter,
and would anticipate some improvement in accuracy in exchange for the additional
computational work required to perform these experiments at higher dimensionalities. In
the BSC, elemental vectors are constructed by distributing an equal number of 1’s and 0’s
at random across the dimensions of the vector concerned. Consequently, elemental vectors
have a high probability of being orthogonal or close-to-orthogonal to each other, with
orthogonality defined as a Hamming Distance (HD) of half the dimensionality of the
vectors concerned (Kanerva et al., 2000; Kanerva, 1994, 1996).
The next step is to generate vector representations of documents, by superposing the
elemental vectors of the terms contained in these documents. With binary vectors,
superposition is accomplished by keeping track of the number of 1’s and 0’s that have been
added in each dimension, and assigning the value in this dimension using the majority rule,
with ties split at random. I will refer to this operation by using the “+”symbol, with “+=”
indicating a superposition that includes the vector on the left of the operator also (so
DOC(D) += E(C) is equivalent to DOC(D) = DOC(D) + E(C), a common operation during
training).
In the experiments, this superposition is weighted using the Log-Entropy weighting
procedure. The local term weight for term i in document j (lij) is derived from the frequency
of a term in a document. The global weight for term i (gi) describes the frequency of the
term within the entire text corpus. They are computed with Equation 1.
This weighting scheme reduces the influence of high frequency terms that may be
uninformative, and tempers the influence of terms that recur frequently within a single
document (Dumais, 1991). Once document vectors have been generated (Equation 2), it is
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possible to generate vector representations of concepts (in this case, or terms in the general
case), known as semantic vectors. I will refer to the semantic vector for concept C as S(C).
Semantic vectors are constructed by superposing vector representations of the documents
a concept occurs in.

𝐿𝑜𝑔𝐸𝑛𝑡𝑟𝑜𝑝𝑦(𝑡𝑒𝑟𝑚 𝑖, 𝑑𝑜𝑐𝑢𝑚𝑒𝑛𝑡 𝑗) = 𝑙𝑖𝑗 × 𝑔𝑖
𝑙𝑖𝑗 = log(𝑡𝑒𝑟𝑚 𝑖, 𝑑𝑜𝑐𝑢𝑚𝑒𝑛𝑡 𝑗) = log(1 + 𝑡𝑓𝑖𝑗 )
𝑝𝑖𝑗 × log 𝑝𝑖𝑗
𝑡𝑓𝑖𝑗
𝑔𝑖 = 𝐸𝑛𝑡𝑟𝑜𝑝𝑦(𝑡𝑒𝑟𝑚 𝑖) = 1 − ∑
, 𝑤ℎ𝑖𝑙𝑒 𝑝𝑖𝑗 =
log 𝑛
𝑔𝑓𝑖
𝑗
𝑡𝑓𝑖𝑗 : 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒𝑠 𝑜𝑓 𝑡𝑒𝑟𝑚 𝑖 𝑖𝑛 𝑑𝑜𝑐𝑢𝑚𝑒𝑛𝑡 𝑗
𝑔𝑓𝑖 : 𝑔𝑙𝑜𝑏𝑎𝑙 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑓𝑜𝑟 𝑡𝑒𝑟𝑚 𝑖 (𝑡𝑜𝑡𝑎𝑙 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒𝑠 𝑜𝑓 𝑡𝑒𝑟𝑚 𝑖 𝑖𝑛 𝑡𝑒𝑥𝑡 𝑐𝑜𝑟𝑝𝑢𝑠)
𝑛: 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑜𝑐𝑢𝑚𝑒𝑛𝑡𝑠 𝑖𝑛 𝑡𝑒𝑥𝑡 𝑐𝑜𝑟𝑝𝑢𝑠
Equation 1: Log-Entropy weighting equation

𝑆(𝑑𝑜𝑐)+= 𝐸(𝑡𝑒𝑟𝑚) ∙ 𝑙𝑜𝑐𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 ∙ 𝑔𝑙𝑜𝑏𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 = 𝐸(𝑡𝑒𝑟𝑚) ∙ 𝑙𝑖𝑗 ∙ 𝑔𝑖
Equation 2: Generating document vectors with weighting procedure in RRI

Superposition of binary vectors requires maintaining a “voting record” that keeps track of
the number of 1’s and 0’s added in each dimension. When local and global weighting
metrics are utilized, the “votes” may not be integer values. So, for example, if the vector
1010 were added with a weight of 0.5, a straightforward implementation of the voting
record would add 0.5 to the dimensions of the voting record corresponding to the 1’s, and
subtract 0.5 from the dimensions corresponding to the 0’s. Normalization involves tallying
these votes. After training is complete, those dimensions of the voting record with positive
values would be assigned 1, those with negative values would be assigned 0, and those
with a zero value would be assigned either 1 or 0 at random. In practice, however, it is
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computationally inconvenient to maintain and update 32,000 real values to serve as a
voting record for each semantic vector. Consequently, the Semantic Vectors package
employs a binary matrix approximation of the voting record, which sacrifices some
floating-point precision in exchange for computational efficiency. These implementation
details are provided in (Widdows & Cohen, 2012).
These operations are expressed concisely in the pseudo code in Figure 4-1, adapted from
(Cohen et al., 2010). A schematic representation for RRI is shown in Figure 4-2. I used
Semantic Vectors Version 3.7 to build RRI vectors. Once semantic vectors were
constructed, the relatedness between drugs and ADRs was estimated as [1 −
2
𝑛

𝐻𝑎𝑚𝑚𝑖𝑛𝑔𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒(𝑥, 𝑦)]. Therefore, a ranked list of ADRs for each drug was

provided.

q := # total terms
n := # dimensions, n := 32, 000
p := # total documents
m := # total UMLS concepts
k := # terms in a speciﬁc document OR # documents related to a speciﬁc concept
⊳ initialize elemental vectors E(T)
for i < q do
generate a zero vector of dimension n
in E(Ti) arbitrarily set half of the zero dimensions to 1
end for
⊳ train document model (E(T), p)
for j < p do
for term i in document j do
DOC(Dj) + = E(Ti) × LogEntropy (term i, doc j)
end for
normalize (DOC (Dj))
end for
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⊳ train concept model (DOC (D), m)
for j < m do
for each of k documents concept j occurs in do
S(Cj) + = DOC(Dk)
end while
normalize (S(Cj))
end for
Figure 4-1: The pseudo code for RRI model training process

Figure 4-2: Schematic representation of RRI training and inference process
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4.2.2 PSI
4.2.2.1 Operations in PSI
The PSI model provides the means to implement discovery patterns for LBD using
distributional semantics (Cohen, Widdows, Schvaneveldt, Davies, et al., 2012; Cohen,
Widdows, Schvaneveldt, & Rindflesch, 2012). This is accomplished by representing
concepts and relationships extracted by SemRep as high-dimensional vectors using an
adaption of RI. In previous work, PSI has been applied to discover therapeutic relationships
(Cohen, Widdows, Schvaneveldt, Davies, et al., 2012) using a two-stage process of
discovery by analogy: first a geometric operator is used to infer discovery patterns from
known treatments, then the identified discovery patterns are used to infer previously unseen
therapeutic relationships.
In addition to the superposition operation described previously, the PSI model utilizes a
binding operation. Binding (⊗) is a compositional operation that is provided by VSAs,
such as the BSC (Gayler, 2004; Kanerva, 1996). Binding two elemental vectors generates
a third vector, which is dissimilar from these two component vectors. The binding
operation is reversible (release ⊘). With binary vectors, pairwise exclusive OR (XOR) is
used to accomplish both binding (⊗) and release (⊘).
4.2.2.2 PSI training process
The training process for generating semantic vectors proceeds as follows:
(1) Generate elemental vectors for all concepts and relations occurring in semantic
predications;
(2) generate a semantic vector for each concept, initially empty;
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(3) for each predication (concept-predicate-concept), bind the elemental vector of one
concept and the elemental vector of the predicate, and add this bound product to the
semantic vector for the other concept.
During step (3), a statistical weighting scheme is applied. For the predication C1 P C2, the
semantic vector S (C2) is generated as shown in Equation 3.

𝑆(𝐶2 )+= 𝐸(𝐶1 ) ∙ 𝑃𝑓 ∙ (𝑖𝑑𝑓𝑃 + 𝑖𝑑𝑓𝐶1 )
Equation 3: Generating second degree of Semantic Vectors

The global weight Pf is derived from the number of times that the predication occurs in the
SemMedDB. The local weight idf (inverse document frequency of the concept C or the
predicate P) reflects the occurrence of the concept across all documents. They are
computed as shown in Equation 4.

𝑃𝑓 = log(1 + 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒𝑠 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝐶1 𝑃 𝐶2
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑝𝑟𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠
𝑖𝑑𝑓𝐶/𝑃 = log(
)
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 𝐶/𝑃
Equation 4: Weighting procedure in PSI

The pseudo code for PSI is displayed in Figure 4-3.

q := # unique UMLS concepts and predicates from SemMedDB
n := # dimensions, n := 32, 000
p := # total predications
k := # predications related to a speciﬁc concept
⊳ initialize elemental vectors E (C) and E (P)
for i < q do
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generate a zero vector of dimension n
in E (Ci) or E (Pi) arbitrarily set half of the zero dimensions to 1
end for
⊳train semantic model (E, p)
for j < p do
predication j: C1 P C2
𝑆(𝐶1 )+= 𝐸(𝐶2 )⨂𝐸(𝑃 − 𝐼𝑁𝑉) ⋅ 𝑃𝑓 ⋅ (𝑖𝑑𝑓𝑃 + 𝑖𝑑𝑓𝐶2 )
𝑆(𝐶2 )+= 𝐸(𝐶1 )⨂𝐸(𝑃) ⋅ 𝑃𝑓 ⋅ (𝑖𝑑𝑓𝑃 + 𝑖𝑑𝑓𝐶1 )
end for
normalize S(C)
Figure 4-3: The Pseudo code for PSI model training process

All concepts and relations were assigned a binary elemental vector of 32,000 bits in length.
The semantic vector of each concept was generated by superposing bound products related
to this concept, where the bound products were produced by binding the elemental vectors
for the other concept and predicate elemental vectors in each predication this concept
occurs in. The search space of SIDER2 side effects contains 3,436 ADRs.
4.2.2.3 Inferring discovery patterns
After training the semantic vectors, the PSI model can be used to infer discovery patterns
by “releasing” the semantic vector of a drug using the semantic vector of its ADR.
The bound product of the drug’s semantic vector and discovery patterns’ vectors can be
subsequently used as a query vector to search the vector space of side effects. In this
procedure, discovery patterns were inferred from all known drug/ADR associations. For
each drug, the five discovery patterns that were most frequently inferred from all other
drugs and their ADRs were retained.
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The pathways connecting drugs to side effects may not be restricted to one middle term
(and two predicates). In previous experiments predicting therapeutic relationships,
performance was improved by including pathways of three predicates and two middle
terms (Cohen, Widdows, Schvaneveldt, & Rindflesch, 2012). This is accomplished by
generating a second-degree semantic vector for a concept, S2(concept), by adding together
the (first-degree) semantic vectors of all concepts connected to it by a predicate of interest.
In the experiments, the two most popular predicates from inferred double-predicate
reasoning pathways -- INTERACTS_WITH and COMPARED_WITH -- were used to
build second-degree semantic vectors S2. This vector is then used as an alternative starting
point for the inference procedure. From this point, the five most frequently inferred doublepredicate reasoning pathways using the second order semantic vector of all other drugs and
the (first order) semantic vectors of their ADRs were retained. As these inferred pathways
connect to drugs through either INTERACTS_WITH or COMPARED_WITH, they are
referred to as triple-predicate pathways.
4.2.2.4 Applying discovery patterns to find possible ADRs (Step 5 in Figure 4-4)
To combine query vectors for frequently inferred reasoning pathways into one search
expression, I use a disjunction operation that originates in the quantum logic of Birkhoff
and von Neumann, and was first applied to information retrieval by Widdows and Peters
(Birkhoff & Von Neumann, 1936; Widdows & Peters, 2003). I define the disjunction of
these five query vectors as a query subspace derived from them using a binary vector
approximation (Cohen, Widdows, De Vine, Schvaneveldt, & Rindflesch, 2012) of the
Gram-Schmidt orthonormalization procedure (Golub & Van Loan, 2012). The length of
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the projection of some other vector in this subspace provides an estimate of vectorsubspace similarity.
For the double-predicate discovery patterns model, a drug’s query subspace was
constructed from this drug’s first-degree semantic vector bound to the vector
representations of the five double predicate reasoning pathways most frequently inferred
from other drugs. For the double- and triple-predicate discovery patterns model, a drug’s
query subspace also included this drug’s second-degree semantic vector bound to vector
representations of the five reasoning pathways most frequently inferred from the seconddegree semantic vectors of other drugs.
The length of the projection of the semantic vector for a candidate ADR into a drug’s query
subspace was used to estimate the relatedness between these entities, providing a ranked
list of potential ADRs for each drug.
Figure 4-4 provides an overview of the PSI-based analogical reasoning process in its
entirety.
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Figure 4-4: Schematic representation of PSI training and inference process.
Triglycerides: TG; myocardial infarction: MI; INTERACTS_WITH: IW;
COEXISTS_WITH: CoeW; ASSOCIATED_WITH: AW; COMPARED_WITH: ComW
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4.3 Experimental design
An overview of the experimental design is shown in Figure 4-5. The first experiment was
conducted without knowledge of drug indications. The concept-based RRI model and
discovery pattern-based PSI model were compared with respect to their ability to identify
known drug/ADR associations. In the second experiment, the model with the best
performance from the first experiment was used to evaluate the effect of eliminating known
indications from the list of predictions.

Figure 4-5: Experimental design in the detection of SIDER2 known ADRs using LBD
distributional semantic models
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4.3.1 Experiment 1 design
Distributional semantic vectors were used to model MMB and SemMedDB. RRI vectors
and PSI vectors formed the basis for the models of LBD concept-based co-occurrence and
LBD discovery patterns, respectively. As MetaMap may retrieve many more concepts from
a particular document than SemRep retrieves predications, I varied the RRI model to assess
the extent to which observed effects were due to the advantage of a more extensive (albeit
less structured) knowledge base. In one case, a RRI space was derived from only those
sentences from which predications were extracted. Consequently, there are three
distributional semantic models -- RRI built from documents (RRI-from-document group),
RRI built from predication source sentences (RRI-from-predication group), and PSI built
from predications. The PSI model was evaluated with two settings. In the first case, only
two-predicate discovery patterns were considered (PSI-double group), while the second
case considered both two- and three-predicate patterns (PSI-double+triple group). The
elemental vectors for terms, which are not meaningfully related to one another, were used
to implement a random baseline (Baseline group).
With the RRI models, for each drug, related problems were sought by comparing each
vector in the side effect search space to this drug’s vector representation.
With the PSI model, SIDER2 known drug-side effect pairs were used to infer predicate
paths. For the PSI-double group, each drug’s query subspace was built as the disjunction
of the bound products between the drug and its five double-predicate reasoning pathways.
For the PSI-double+triple group, each drug’s query subspace additionally included the
second degree semantic vector of this drug bound to five triple-predicate paths. The five
triple-predicate paths were retrieved by the extension of second degree semantic vectors of
70

drugs. Comparing a drug’s query subspace with each vector in the search space allowed us
to infer the drug’s possible side effects.

4.3.2 Experiment 2 design
From preliminary results, I found that there were some indications in the inferred ADRs.
So I hypothesized that excluding known indications for drugs from the search space would
improve performance. I tested this hypothesis in the second experiment utilizing
knowledge of drug indications from MEDI. In this experiment, I tested variants of the
MEDI indication list using the best performing model from the first experiment (PSI double
+ triple group). I extended the MEDI-complete and MEDI-HPS lists to include all
offspring, or immediate offspring nodes based on the UMLS semantic network utilizing
the MRREL.RRF file. This file includes relationships between UMLS concepts found in
the UMLS Metathesaurus (U. S. National Library of Medicine, 2009). By utilizing these
ancestor-offspring hierarchical relationships, I define an offspring node as a node that has
a MEDI indication as an ancestor (regardless of the number of intervening nodes); and an
immediate offspring node as a node that has this MEDI indication as its parent.
In this procedure, I first normalized all MEDI terms. For MEDI drugs, I mapped each
drug’s RxCUI to a UMLS CUI with the RxNorm API (U.S. National Library of Medicine
& National Institutes of Health, 2014) and then searched the UMLS CUI in SemMedDB
and MMB to retrieve the mapped UMLS concept. For MEDI indications, I mapped each
indication’s ICD-9 term to a UMLS CUI using the UTS API 2.0 (U.S. National Library of
Medicine & National Institutes of Health, 2012) and then subsequently searched for this
UMLS CUI in SemMedDB and MMB to retrieve the mapped UMLS concept. After
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normalizing MEDI terms, the hierarchical relation of synonym (SY), child (CHD), and
sibling (SIB) in MRREL.RRF were used to find drugs’ MEDI indications extended
offspring or immediate offspring. Consequently, there were six MEDI lists (Table 4-1).
These MEDI lists were used to exclude indications from the side effect search space and
were tested in the second experiment.

Table 4-1: Different groups by extending MEDI in experiment 2
MEDI intervention
Extension Procedure
Experiment Group
No MEDI
None
No-MEDI group
None
MEDI-HPS group
All synonym (SY), child (CHD),
MEDI-HPS-offspring
MEDI-HPS
and sibling (SIB), as well as their
group
indications for
offspring.
SIDER2 drugs
Immediate synonym (SY), child
MEDI-HPS-immediate
(CHD), and sibling (SIB)
offspring group
relationships.
None
MEDI-complete group
All synonym (SY), child (CHD),
MEDI-complete-offspring
MEDI-complete
and sibling (SIB), as well as their
group
indications for
offspring.
SIDER2 drugs
Immediate synonym (SY), child
MEDI-complete(CHD), and sibling (SIB)
immediate offspring group
relationships.

4.3.3 Performance measurements
To evaluate performance, I used a number of widely used metrics. Precision measures the
proportion of accurate ADRs in relation to the total number of ADRs retrieved (Salton,
Fox, & Wu, 1983). To evaluate the precision at different points in a ranked list, I used
average precision (AP, the average of the precision values measured at the point at which
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each correct result is retrieved for one example (Manning, Raghavan, & Schütze, 2008)).
Mean average precision (MAP) is the average of the AP across all drugs. Precision at k
(Manning et al., 2008) measures the precision at fixed levels of retrieved results and
emphasizes the importance of finding relevant results early. I evaluated precision at k=50
(Pk=50). Recall represents the proportion of ADRs retrieved out of the total number of ADR
associations in the reference standard (Salton et al., 1983).
A “rediscovery” (true discovery) is defined as an adverse effect inferred by a vector model
and subsequently confirmed by SIDER2 as a true prediction. Consequently, the median
rediscovery rank for a particular drug approximates the point in the ranked list produced
by a particular model at which half of the known adverse reactions for this drug were
recovered.
The AP and median rank of the rediscoveries across drugs were compared by the paired t
test and the Wilcoxon matched-pairs signed-rank test, respectively.
To measure the performance with respect to the true positive rate (TPR) and false positive
rate (FPR), receiver operating characteristic (ROC) curve was plotted for all drug/ADR
pairs for all models. Subsequently, a global area under the ROC curve (AUC, “global”
indicates that the scores of all drug/ADR pairs were combined into a single curve) was
calculated using AUCCalculator (Davis & Goadrich, 2006). For the model with the best
global AUC, a drug-based AUC was also calculated and compared between drugs.

4.4 Results
4.4.1 Experiment 1
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4.4.1.1 Inferring discovery patterns
The most strongly associated double-predicate path was calculated for each known
drug/ADR pair. In total, 90,787 predicate paths were inferred. Among them, there were
1,485 unique predicate paths. The five most frequently inferred double-predicate paths
were selected. Second degree semantic vectors for drugs were constructed by adding
together the semantic vector representations of any concept occurring in a semantic
predication with the drug in question, where the predicate type was either
INTERACTS_WITH or COMPARED_WITH. The most frequently occurring double
predicate paths and inferred triple predicate paths with corresponding examples are shown
in Table 4-2. They are consistent across all drugs. Many of these paths are readily
interpretable, and could support a plausible biological mechanism for a predicted effect.
For example, INTERACTS_WITH:CAUSES-INV suggests a drug may interfere with
some biological factor which may cause a side effect. COMPARED_WITH:CAUSES-INV
can be used to identify similar side effects by comparing their drug class information as
COMPARED_WITH often indicates a comparative evaluation across different drugs in the
same therapeutic category. Triple predicate paths extend the connecting path for drugs and
related ADRs.

Table 4-2: The most frequent predicate paths in inferred discovery patterns
double/triplepredicate
INTERACTS_WITH
CAUSES-INV

Example

dipyridamole INTERACTS_WITH nitric oxide
bradycardia CAUSES-INV nitric oxide
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double/triplepredicate

Example

ASSOCIATED_WITH
COEXISTS_WITH

rosiglitazone COEXISTS_WITH apolipoprotein a-ii
apolipoprotein a-ii ASSOCIATED_WITH myocardial
infarction

COMPARED_WITH
CAUSES-INV

bisoprolol COMPARED_WITH metoprolol
hypotension CAUSES-INV metoprolol

ASSOCIATED_WITH
INTERACTS_WITH

rosiglitazone INTERACTS_WITH triglycerides
triglycerides ASSOCIATED_WITH myocardial infarction

ISA
CAUSES-INV

naproxen ISA calcineurin inhibitor
toxic nephropathy CAUSES-INV calcineurin inhibitor

INTERACTS_WITH
INTERACTS_WITH
ASSOCIATED_WITH

rosiglitazone INTERACTS_WITH lyrm1
lyrm1 INTERACTS_WITH fatty acids, nonesterified
fatty acides, nonesterified ASSOCIATED_WITH
myocardial infarction

INTERACTS_WITH
ASSOCIATED_WITH
COEXISTS_WITH

rosiglitazone INTERACTS_WITH glycerol-3-phosphate
dehydrogenase
glycerol-3-phosphate dehydrogenase COEXISTS_WITH
succinate dehydrogenase
Succinate dehydrogenase ASSOCIATED_WITH
myocardial infarction

COMPARED_WITH
INTERACTS_WITH
ASSOCIATED_WITH

rosiglitazone COMPARED_WITH glycerophosphates
glycerophosphates INTERACTS_WITH low-density
lipoproteins
low-density lipoproteins ASSOCIATED_WITH
myocardial infarction

COMPARED_WITH
COEXISTS_WITH
ASSOCIATED_WITH

rosiglitazone COMPARED_WITH gw 501516
gw 501516 COEXISTS_WITH high-density lipoprotein
cholesterol
high-density lipoprotein cholesterol
ASSOCIATED_WITH myocardial infarction
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4.4.1.2 Performance
Results for different vector models are shown in Table 4-3. PSI-based models performed
better than RRI-based models and both models perform better than the random baseline.
The PSI-double + triple group outperformed all other groups. All differences in median
rank and AP were statistically significant (as estimated by Wilcoxon’s signed rank test and
paired t test respectively). Pk=50 for each drug was compared across groups using Pearson’s
correlation. For variants of the same model (RRI or PSI), Pk=50 was highly correlated (0.750.84). Correlation in Pk=50 between the PSI and RRI models was between 0.52 and 0.57,
suggesting the potential to improve performance by combining results.

Table 4-3: Results of precision and rank-based measures for different groups
Group
MAP Pk=50 for all drugs
Median Rank
AUROC
(global precision)
(n=3,436)
median mean
Baseline group
0.0300 0.0284
1708
1711.44
0.5021
RRI-from-predication
0.0365 0.0469
1629
1651.08
0.5140
group
RRI-from-document
0.0520 0.0784
1333
1454.30
0.5508
group
PSI-double group
0.0591 0.0942
1233
1379.65
0.5973
PSI-double+triple
0.0848 0.1410
808
1108.47
0.6841
group

4.4.1.3 AUC
Figure 4-6 and Table 4-3 present the global ROC curves for all models. ROC curve shows
the tradeoff between sensitivity and specificity. The global AUC provides a cumulative
estimate of accuracy, and is shown for each model in Table 4-3. PSI-double+triple group
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has the best global AUC of 0.6841. I measured its AUC at the drug level (Figure 4-7). The
mean and median AUC are 0.7102 ± 0.0752 and 0.7058 respectively. Figure 4-7 shows a
plot of the AUC for each drug against the log of the number of predications in SemMedDB
with this drug as subject. This suggests a trend in which performance is generally better for
those drugs for which more knowledge is available in the database. Those drugs with an
AUC of 0.8 or above tend to occur in 10,000 or more predications as subject.
Note that the global AUC as a metric will be inflated by methods that incorporate category
bias into their prediction (Akbani, Kwek, & Japkowicz, 2004; Liu, Wu, et al., 2012), a
subject I will return to in the discussion section.

Figure 4-6: ROC plot of true positive rate and false positive rate for all groups
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Figure 4-7: Performance of AUC for all drugs by PSI-double+triple group

4.4.1.4 Rediscovery results
The results of this experiment are illustrated in Figure 4-8. This figure plots the number of
rediscovered side effects (left Y axis) and the proportion of the valid side effects
rediscovered (or global recall, right Y axis) for each model against the mean number of
suggested potential ADRs (X axis) at different statistical thresholds. All distributional
models outperform the random baseline.
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Figure 4-8: Rediscovery plot for experiment groups

With approximately 100 predictions per drug, baseline, RRI-from-predication, RRI-fromdocument, PSI-double and PSI-double+triple group have a global recall of 0.029, 0.045,
0.069, 0.088, 0.125, respectively.
4.4.2 Experiment 2
The PSI-double+triple model was the best performing model in the first experiment, and
was selected to test the effects of using variants of the MEDI list as a way to exclude
therapeutic relationships to reduce the number of highly ranked false positive predictions.
Table 4-4 presents the performance of the PSI-double+triple model when different MEDI
lists were used. The median rank of true positive predictions was lower when MEDI was
used to exclude the indication from the search space for each drug. However, as median
79

rank is based on the rank of true positive results only, it does not consider known side
effects that may have been excluded from consideration by the MEDI list. In contrast, MAP
also measures whether true side effects have been excluded. Consequently, MAP in the
MEDI-complete-immediate offspring was higher than other groups. Overall, AUC was
highest for the MEDI-HPS-immediate offspring group. Of the models, only the MEDIHPS-immediate offspring group outperformed the baseline PSI model by all metrics, and
the improvements in performance were small in comparison with the differences in
performance between distributional models in experiment 1. All differences between all
MEDI intervention groups and No-MEDI group in Pk=50 are statistically significant as
measured by the paired t test. However, the improvement in cumulative accuracy is
negligible.

Table 4-4: PSI-double+triple model performance across all tests with different MEDI
lists. Best results are in boldface. Performance exceeding the baseline (results obtained
by the best PSI model without MEDI) is marked with an asterisk (*)
Group
MAP
Pk=50 for all
Median Rank
AUC
drugs
median
mean
No-MEDI group
0.0848
0.1410
808
1108.468
0.6841
MEDI-HPS group
0.0849*
0.1417*
807*
1107.595* 0.6839
MEDI-HPS-offspring
0.0798
0.1283
765*
1050.745* 0.6813
group
MEDI-HPS-immediate
0.0866*
0.1444*
795*
1094.41*
0.6850*
offspring group
MEDI-complete group
0.0839
0.1401
809
1108.062* 0.6831
MEDI-complete0.0673
0.0917
0.6737
681*
953.761*
offspring group
MEDI-complete773*
1068.718* 0.6821
0.0889*
0.1467*
immediate offspring
group
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4.4.3 Plausibility evidence found by PSI discovery patterns approach
In this paper, the association between rosiglitazone and myocardial infarction, a highly
publicized ADR discovered after the drug was released to the market, is used to illustrate
how evidence from the literature can be retrieved for the evaluation of plausibility by a
domain expert. The term “myocardial_infarction” was ranked in the top 1% (rank=29) and
top 1.5% (rank=50) of potential side effects for rosiglitazone by the PSI-double and PSIdouble+triple models respectively.
Rosiglitazone is a thiazolidinedione (TZD) antidiabetic drug, used to treat type 2 diabetes
mellitus as an adjunct to lifestyle changes (Cheung, 2010; Hamblin, Chang, Fan, Zhang, &
Chen, 2009; Lygate et al., 2003). Since its approval by the FDA in 1999, rosiglitazone was
prescribed 3.8 million times annually up to June 2009 in the United States (Shah et al.,
2010). A meta-analysis of clinical trials conducted by Nissen (Nissen & Wolski, 2007) in
2007 suggested that the use of rosiglitazone was associated with a significant increase in
the risk of myocardial infarction. This led to rosiglitazone’s withdrawal from the European
market in 2010 and a rosiglitazone black-box warning in the U.S. (Berthet, Olivier,
Montastruc, & Lapeyre-Mestre, 2011; Shah et al., 2010). In 2013, the FDA lifted some
prescription restrictions in the U.S. market based on a reevaluation of the Rosiglitazone
Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD)
trial (ClinicalTrials.gov Identifier NCT00379769) (U.S. Food and Drug Administration,
2013), but the European suspension is still in effect at the time of this writing.
Rosiglitazone is a nuclear peroxisome proliferator-activated receptor (PPAR-gamma)
agonist. The mechanism through which rosiglitazone causes cardiovascular events is
unclear, but is thought to be related to unfavorable effects on triglycerides, low-density
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lipoprotein cholesterol (LDL-C) particle size and density, and greater affinity for PPARgamma than other TZD drugs (Bourg & Phillips, 2012; Goldberg et al., 2005; Khanderia,
Pop-Busui, & Eagle, 2008; Y. K. Loke et al., 2011). To evaluate the extent to which these
hypotheses were consistent with information utilized by the PSI-double+triple model, I
reconstructed the pathways of predicates and concepts that were consistent with the
inferred discovery patterns used to make this prediction.
For myocardial infarction, each discovery pattern that was used for the inference was used
to search the indexed SemMedDB predications and find middle terms that connect
rosiglitazone with myocardial infarction through the discovery pattern. The middle terms
retrieved were ranked based on their inverse document frequency. Since the indexed
SemMedDB predications contain the source literature ID (PMID), I also retrieved related
literature evidence that supports the prediction.
Consequently 108,100 unique predication pathways were retrieved through 8 unique
predicate paths (Table 4-5) and with 1,601 distinct middle terms that connect rosiglitazone
with myocardial infarction. Table 4-6 shows some example predication pathways that were
composed of two or three predications. There were around 17 sentences providing evidence
to support each predication on average. I analyzed middle terms’ semantic groups
(Bodenreider & McCray, 2003) and list the sample with distinct predicate paths connecting
with different semantic groups (Figure 4-9).
Table 4-5: Reasoning pathways used to retrieve evidence from the literature for the pair
rosiglitazone -- myocardial infarction
Predicate Path
COMPARED_WITH : COEXISTS_WITH : ASSOCIATED_WITH
COMPARED_WITH : INTERACTS_WITH : ASSOCIATED_WITH
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Predicate Path
INTERACTS_WITH : COEXISTS_WITH : ASSOCIATED_WITH
INTERACTS_WITH : INTERACTS_WITH : ASSOCIATED_WITH
COEXISTS_WITH : ASSOCIATED_WITH
INTERACTS_WITH : ASSOCIATED_WITH
COMPARED_WITH : ASSOCIATED_WITH : COEXISTS_WITH
INTERACTS_WITH : ASSOCIATED_WITH : COEXISTS_WITH

Table 4-6: Some example predications for possible mechanism of rosiglitazone causing
myocardial infarction
Middle term “LDL cholesterol lipoprotein”; 123 unique predication pathways; for
example:
rosiglitazone INTERACTS_WITH apolipoproteins_b (Brackenridge et al., 2009;
Sarafidis et al., 2005) INTERACTS_WITH ldl_cholesterol_lipoproteins (Vessby,
Kostner, Lithell, & Thomis, 1982) ASSOCIATED_WITH myocardial_infarction
(Goldberg et al., 2005)
rosiglitazone INTERACTS_WITH paraoxonase_1 (van Wijk et al., 2006)
INTERACTS_WITH ldl_cholesterol_lipoproteins (Gupta, Singh, Maturu, Sharma, &
Gill, 2011) ASSOCIATED_WITH myocardial_infarction (Tetsuro Yoshida et al.,
2010)
Middle term “triglyceride”; 1515 unique predication pathways; for example:
rosiglitazone COEXISTS_WITH triglycerides (Goldberg et al., 2005)
ASSOCIATED_WITH myocardial_infarction (De Caterina et al., 2011; Friis-Moller et
al., 2003; Kuller Lewis et al., 2002; Lekhal, Børvik, Brodin, Nordøy, & Hansen, 2010;
Phillips, 1977)
rosiglitazone INTERACTS_WITH triglycerides (Chao et al., 2000; Nadeau, Ehlers,
Aguirre, Reusch, & Draznin, 2007) ASSOCIATED_WITH myocardial_infarction
rosiglitazone INTERACTS_WITH glycerol-3-phosphate_dehydrogenase (Suzuki,
Suzuki, Sembon, Fuchimoto, & Onishi, 2013) COEXISTS_WITH triglycerides (Im &
Hoopes, 1983) ASSOCIATED_WITH myocardial_infarction
Middle term “ppar_gamma”; 992 unique predication pathways; for example:
rosiglitazone COEXISTS_WITH ppar_gamma (Egerod et al., 2009; Johnson et al.,
2000; Otake et al., 2011; Risérus et al., 2005) ASSOCIATED_WITH
myocardial_infarction (Fliegner et al., 2008)
rosiglitazone INTERACTS_WITH ppar_gamma (Gao et al., 2007; Kim, 2006; Lee,
2003; Tsukahara, 2006; Tzameli, 2004) ASSOCIATED_WITH myocardial_infarction
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rosiglitazone INTERACTS_WITH glycerol-3-phosphate_dehydrogenase (Suzuki et
al., 2013) COEXISTS_WITH ppar_gamma (Muhlhausler, Duffield, & McMillen,
2007) ASSOCIATED_WITH myocardial_infarction
rosiglitazone INTERACTS_WITH glycerol-3-phosphate_dehydrogenase
INTERACTS_WITH ppar_gamma (Ding, Nagai, & Woo, 2003)
ASSOCIATED_WITH myocardial_infarction
rosiglitazone INTERACTS_WITH resistin (Jung et al., 2005) INTERACTS_WITH
ppar_gamma (Patel et al., 2003) ASSOCIATED_WITH myocardial_infarction
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Figure 4-9: The predications retrieved by reasoning pathway for rosiglitazone causing
myocardial infarction with specifying semantic groups for concepts
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There were 2,618 distinct predication pathways about “triglycerides”, “LDL-C” and
“PPAR-gamma” specifying 247 unique middle terms. Drilling down, Figure 4-10 shows
the connecting concepts between LDL-C and myocardial infarction that fall along the
reasoning pathways employed by the PSI-double+triple model. In each reasoning pathway,
the middle terms were ranked using inverse document frequency, to approximate the
weighting used by the predictive model. For each predication in these pathways, the source
sentences from the literature were retrieved. For example, the article “A comparison of
lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes
and dyslipidemia” (Boyle et al., 2002) explains that rosiglitazone increased triglycerides
compared with pioglitazone and has different effect on plasma lipids which may contribute
to heart disease. Figure 4-10 shows the middle terms retrieved to justify that rosiglitazone
may cause myocardial infarction via LDL-C.
The capacity to retrieve and organize knowledge in this way suggests a new paradigm for
information retrieval in which information supporting a hypothesis of interest is
automatically aggregated and organized at the conceptual level. However, as the number
of assertions in the literature far exceeds the number of documents, further research is
needed to develop methods through which to prioritize these assertions, and present them
in a manner conducive to human consumption.
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Figure 4-10: Middle terms that were retrieved by PSI discovery patterns involving LDLC
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4.5 Discussion
This study evaluates the ability of scalable LBD methods based on distributional semantics
to rank the plausibility of connections between drugs and potential ADRs. I find that both
the RRI and PSI models are able to retrieve known side effects of drugs, but PSI performs
this task better, as one would anticipate given the additional information beyond cooccurrence that it encodes. The PSI model can further provide the reasoning pathways that
were used to link a drug to a predicted side effect. Consequently, relevant literature can be
retrieved to support the predictions, and provided to experts for review. However further
research is needed to develop approaches through which the assertions underlying the large
numbers of reasoning pathways utilized by the model can be prioritized for expert review,
as these are too numerous for exhaustive manual review. Ultimately, I aim to provide
domain experts with essential evidence while preventing information over-load. Even
though it is not the best performing model, the RRI model has the advantages of a simple
training process and the availability of more data to draw upon (as MetaMap has higher
recall for concepts than SemRep has for predications). Conversely, the PSI model has the
advantage of modeling plausibility, a capability with the potential to assist expert clinical
review for pharmacovigilance. In addition, the correlation analysis between groups
suggests that RRI and PSI complement each other, and can potentially be combined to
improve performance on this task.
For predicting ADRs, several statistical models and Machine Learning (ML) algorithms
have been evaluated against an edition of SIDER, or a subset of this repository. In addition
to methodological differences, these approaches have leveraged different data sets and a
variety of knowledge bases as a basis for making predictions. In the section that follows, I
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will provide a review of these approaches, and the performance they have documented for
the prediction of ADRs in SIDER.
Pauwels et al. represented drugs using as features the presence or absence of chemical
substructure components described in PubChem (B. Chen, Wild, & Guha, 2009). In
addition to standard supervised ML approaches, they applied canonical correlation analysis
(CCA), including a sparse variant that emphasizes a small number of informative features
for each training example. These methods were used to predict SIDER side effects, with a
reported global AUC of 0.8932 (Pauwels et al., 2011) on a set of 1350 ADR and 888 drugs,
using fivefold cross-validation.
Subsequently, Liu et al. applied five supervised ML algorithms to the same SIDER set. In
addition to the PubChem-derived chemical substructure features used by Pauwels et al.,
features were drawn from DrugBank (Knox et al., 2011) (drug targets, transporters, and
enzymes), KEGG (Kanehisa & Goto, 2000) (pathway information) and SIDER itself (drug
indications and side effects). A classifier was built for each SIDER ADR, and the classifiers
were then evaluated on 832 SIDER drugs (for which DrugBank IDs could be found) using
fivefold cross-validation. The support vector machine (SVM) algorithm performed best
with a global AUC of 0.9524 on the full SIDER dataset (Liu, Wu, et al., 2012). The authors
attribute much of the improvement in performance by this and other metrics to the effects
of incorporating SIDER side effects as features, suggesting that certain side effects have a
tendency to co-occur in drug label data.
Other authors have reported performance on subsets of SIDER using similar methods. For
cardio-toxicity related ADRs in SIDER, a median AUC of 0.771 using SVM for prediction
has been reported (Huang et al., 2011). In this case, features were selected from information
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about intended drug targets in DrugBank, and information about off-target effects from an
expanded protein-protein interaction network developed using gene ontology (GO)
annotations. A SVM classifier was built for each evaluated ADR and cross-validated on
SIDER.
With respect to performance, two of these studies, Pauwels et al. (Pauwels et al., 2011) and
Liu et al. (Liu, Wu, et al., 2012) report a global AUC of close to 0.9 or higher with the best
of their methods. Though the results are not directly comparable as I made predictions on
a per-drug rather than a per-ADR basis, the difference between the global AUC of these
methods and that obtained with our approach seems large. However this difference in
global AUC is misleading. As noted by Liu and colleagues in their paper, the imbalance
between positive and negative examples across ADRs and the way in which the global
AUC was calculated in this work leads to an apparent inconsistency between it and the
other evaluation metrics presented. For example, Pauwels and his colleagues display the
AUC across different ADRs in a series of box plots, which shows a median AUC for the
best-performing method (by this metric) of slightly above 0.6. Acknowledging this issue,
Liu et al. also report precision and recall for each evaluated method with, for example,
precision of 0.66 and recall of 0.63 for SVMs with their maximal feature set. Notably, the
AUC in this case was around 0.95.
This apparent inconsistency can be explained by the effect of the prevalence of positive
examples for each ADR on the prediction strength. This is readily apparent for simple
algorithms such as Naive Bayes, where the prior probability of a given category is
incorporated into the estimate. However, it is also an issue for more sophisticated
algorithms such as SVM (Akbani et al., 2004) particularly when the imbalance between
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categories is severe. This is the case for many of the ADR examples: Liu et al. report a
positive to negative ratio of around 1:166 for 554 of the 1135 ADRs. So given the same set
of features, instances in these cases are likely to receive a lower prediction score than those
in balanced cases. When these scores are aggregated across examples to generate a global
AUC, ML methods that incorporate the category bias will obtain an inflated global AUC
on account of this tendency to assign lower scores to instances with few positive examples.
However, as noted by Liu et al. and demonstrated by the other reported metrics, this AUC
is not an accurate reflection of the ability of these models to detect positive examples.
To simulate the effects of category bias on global AUC, I performed a simple experiment
in which I multiplied the similarity scores produced by our model by the proportion of
positive examples for each drug. This roughly approximates the effects of an accurately
estimated prior class probability during cross-validation experiments. This resulted in an
increase of our global AUC from 0.68 to 0.88. I do not present this result for the purpose
of comparative evaluation, as our experiments are not directly comparable with prior ML
work for other reasons I will subsequently discuss. Rather, I present it as an illustration of
the disproportionate influence of category bias on global AUC, which underscores the
issues with this evaluation metric raised by Liu et al. I trust it will also serve to dispel the
misleading impression that the predictive accuracy of our methods is vastly inferior to that
reported previously.
As our method does not consider the number of ADRs associated with a particular drug,
the global AUC and median AUC approximately agree with one another. Our median AUC
(across all drugs) of 0.7058, which falls somewhere in between that reported by Pauwels
et al. (Pauwels et al., 2011) (across all ADRs) and Huang et al. (Huang et al., 2011) (across
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cardio-toxicity related ADRs only). On account of the difference in denominator these
results are not directly comparable, but they do further illustrate the discrepancy between
global and local AUC in models that are not agnostic to class imbalance. Arguably such
agnosticism is desirable from the perspective of an expert review, as it is difficult to justify
the assertion that those drugs with fewer known associated side effects should be
considered less likely to cause some newly observed side effect (and vice versa).
With respect to methodological differences, all of the above methods are supervised ML
methods, and were applied to infer whether or not drugs were associated with each ADR
from the features of other drugs known to be associated with this ADR. So the predictive
models were generally customized on a per-ADR basis, for example by generating an
individual classifier for each ADR in the case of SVM. In contrast, our approach infers a
set of abstract reasoning pathways that were consistent across the drugs I evaluated.
However, as illustrated by the absence of evidence across certain pathways in the
rosiglitazone example, some pathways may be more predictive for particular medications
or ADRs. So it seems likely that I could further improve our performance by incorporating
supervised ML, a direction I plan to explore in future work.
Our approach differs with respect to the knowledge sources utilized also. For example,
KEGG and DrugBank are manually curated databases. Our knowledge base, SemMedDB,
contains predications that have been automatically extracted by SemRep from the
biomedical literature using NLP. Inaccuracies in language processing, or indeed in the
literature itself may introduce sources of error that are not present in manually curated data.
However, the scope of the literature is much broader than that of human-curated resources.
Furthermore, as there is no agreed-upon gold standard for ADRs, different studies have
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utilized different datasets as reference sets (Tatonetti et al., 2012). Our study employed
SIDER2, which includes considerably more drugs and ADRs than SIDER1.
This work has several limitations. The first of these concerns the use of SIDER2 as a
reference standard. As SIDER2 consists of recognized side effects only, I cannot reliably
distinguish between false positive signals and previously unknown ADRs. Furthermore,
SIDER was compiled from package insert information by NLP tools (Kuhn et al., 2010),
and as such may include side effects that seldom occur in practice or false associations that
were caused by text-mining errors (Kuhn et al., 2013). While SIDER2 is sufficient to
evaluate the hypotheses of the current work, in future work I plan to incorporate other data
sources, such as EHR data and FDA reports. These data sources may provide additional
evidence to support the assertion that an unknown drug/ADR pair is worth investigating
further. Alternatively, they may provide the means to select a subset of the side effects in
SIDER2 that have been observed frequently in practice as an additional evaluation set.
Secondly, the MMB repository contains one year less literature than the SemMedDB
dataset. There is a difference of 1,7579,64 citations (7.9% of SemMedDB dataset). These
were the newest datasets at the time of the experiment. However the MMB repository has
many more data points than SemMedDB. For example, more than 99.99% of citations have
concepts extracted by MetaMap and 59.91% of citations have predications extracted by
SemRep.
Another concern is the existing knowledge about causal relationships between drugs and
related ADRs from the literature. For our dataset (90,787 pairs), 45% of pairs (concerning
953 drugs) co-occur directly in the MMB repository and 5% of pairs (concerning 693
drugs) have direct causal relationship (drug CAUSES ADR) in SemMedDB. So PSI’s
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accuracy is dependent upon its ability to meaningfully infer connections between concepts
that were not previously linked in its database, a capacity that would be particularly useful
as a means of assessing novel ADRs that had not previously been documented in the
literature. RRI is also able to draw such inferences, but in this case more of its performance
may be attributable to direct co-occurrence.
Inspecting the middle terms that our model retrieved for rosiglitazone-myocardial
infarction association (Figure 4-10), I found that at times uninformative high-level
concepts, such as “genes” and “proteins”, were retrieved. In our study, I addressed the issue
of uninformative high level concepts in two ways, both related to their propensity to occur
relatively frequently in the corpus. Firstly I used a frequency threshold of 1,000,000 to
exclude frequently occurring concepts contained in SemMedDB. The frequency of “genes”
and “proteins” is less than the threshold and cannot be filtered. Secondly, I used a weighting
procedure to reduce the influence of high-frequency terms on the training process.
However, more sophisticated approaches to filtering are possible. Information concerning
UMLS semantic types and position in the UMLS hierarchy could be used to develop more
sophisticated approaches, to further filter out uninformative high-level concepts, which
may improve performance.
The predictions made by PSI depend upon assertions extracted from the biomedical
literature. One concern about the extracted predications is that they may be implausible on
account of NLP errors. Though SemRep has been optimized for precision, its precision is
not perfect. For example, Kilicoglu and colleagues estimate the precision of SemRep to be
around 0.77 (Kilicoglu et al., 2008). Based on this, and other published evaluations (Ahlers,
Fiszman, Demner-Fushman, Lang, & Rindflesch, 2007; Kilicoglu et al., 2010), it is
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reasonable to estimate that around three in four predications in the set are perfectly
accurate. In many cases, inaccurate predications nonetheless indicate co-occurrence, which
is also informative. The PSI-based analogical reasoning approach I have employed is
robust to isolated language processing errors, as highly ranked predictions are based on
assertions extracted from thousands of unique reasoning pathways. For example, for the
rosiglitazone-myocardial infarction association, 108,100 unique predications were
retrieved, spanning eight of the inferred reasoning pathways. On average, individual
predications were supported by 17 excerpts from the literature. If I extrapolate from prior
published evaluations of SemRep, the predication concerned would have been accurately
extracted from around 12 of these excerpts. So it is likely that at least some of the evidence
supporting each individual assertion is accurate. Moreover, as this method is distributional
in nature, it does not require that these assertions be perfectly accurate. Rather, the
frequency with which an assertion is extracted factors into the strength of its contribution
to a reasoning pathway. Nonetheless, the biomedical literature may contain controversial
assertions, or contradictory conclusions from different experts or different experiments.
This is illustrated by the rosiglitazone (brand name: Avandia) case. In 2007, the FDA added
a black-box warning for heart-related risks to Avandia based on a meta-analysis (Nissen &
Wolski, 2007) and three other studies (U.S. Food and Drug Administration, 2007). In 2013,
the FDA lifted certain Avandia prescribing restrictions based on the readjudicated results
of the RECORD trial (R. D. Lopes et al., 2013; Mahaffey et al., 2013), claiming the initial
concerns were overblown (U.S. Food and Drug Administration, 2013). This decision was
condemned by one of the authors of the original meta-analysis (Thompson, 2013).
Currently our models weight the contribution of assertions using statistics related to local
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and global frequency. However, it would also be possible to weight the importance of these
assertions based on some assessment of the reliability of the source. For example, in
information retrieval experiments, an approach incorporating citation information was
better able to identify articles considered as important in a pre-existing bibliography
(Herskovic & Bernstam, 2005). Possibilities include weights derived from the citation
count of the source article, the impact factor of the journal, or the nature of the experiment
described. It is possible that weighting metrics of this source would improve the predictions
of our models, and they also suggest approaches to prioritize the large numbers of
assertions supporting our predictions for review by human experts.

4.6 Conclusion
In this research, an emerging, scalable method of LBD that uses distributional statistics to
infer and apply discovery patterns was adapted to evaluate the plausibility of drug/ADR
relationships for the purpose of pharmacovigilance. The effective application of large
amounts of partially accurate biomedical knowledge to this problem was facilitated by the
scalable and robust nature of approximate inference in geometric space. This approach was
shown to be more effective than a comparable co-occurrence based baseline, and has the
further benefit of permitting the retrieval of evidence underlying the assertions used by the
system to make its predictions. Consequently, our approach provides the means to assist
with expert clinical review by providing evidence supporting the plausibility of the
connection between drugs and ADRs. Furthermore, the models I have developed can be
applied to filter drug/ADR signals that are detected in spontaneous reporting systems or
EHR data, a direction I plan to explore in future work.
96

Chapter 5: Toward a Reality-based Repository of Adverse Drug Reactions:
Comparing SIDER2 with Side Events Encountered in Practice
Recent informatics research has focused on the development and evaluation of automated
approaches to pharmacovigilance (D. J. Almenoff et al., 2005; Andrew Bate, 2003; Wang
et al., 2009). However, since the purpose of pharmacovigilance is to monitor and predict
previously unknown side effects, there is no complete reference set with which to validate
detected drug/ADR associations. Nonetheless, there is a need for such a gold standard in
pharmacovigilance (Manfred Hauben & Aronson, 2007). For example, a reference set is
required to evaluate a signal detection algorithm or validate the predictions of a
pharmacovigilance system. As it is not practical to construct a large-scale validation set
consisting of previously unknown side effects, common strategies involve validation
against published drug reference book (Lindquist et al., 2000), drug safety related labelling
changes (Manfred Hauben & Reich, 2004), curated reference sets (Coloma et al., 2013;
LePendu et al., 2013; Ryan et al., 2012; Ryan, Schuemie, Welebob, et al., 2013), or largescale database of known drug/ADR associations (Kuhn et al., 2010).
The EU-ADR (Coloma et al., 2013) and the Observational Medical Outcomes Partnership
(OMOP) (Ryan et al., 2012; Ryan, Schuemie, Welebob, et al., 2013), major drug
surveillance projects in Europe and America, systematically developed small curated
reference sets for evaluating their new developed methods on drug safety surveillance with
observational healthcare data (for example, administrative claims and EHRs). The EU97

ADR reference standard (Coloma et al., 2013) contains 94 drug-event associations (44
positives and 50 negatives). This was constructed based on literature, WHO Vigibase TM
(WHO spontaneous reporting system (SRS)) and clinical adjudication. These associations
were restricted to ten important events in pharmacovigilance and are adequately
represented in the EU-ADR network. With the experiences of previous OMOP experiments
and stakeholder interest, OMOP selected four events to construct a reference standard for
methodology evaluation. The OMOP reference standard (Ryan, Schuemie, Welebob, et al.,
2013) contains 399 drug-event associations (165 positive controls and 234 negative
controls) that were developed from drug labeling, Tisdale level of causative evidence
review (James E. Tisdale & Douglas A Miller, 2010) and systematic literature review.
These associations are also required to have sufficient representations in OMOP databases.
These two reference standards have been applied to evaluate different statistical methods
in discriminating true effects from false drug-event associations with the EU-ADR
databases (Schuemie et al., 2012, 2013) and the OMOP databases (William DuMouchel,
Ryan, Schuemie, & Madigan, 2013; Madigan, Schuemie, & Ryan, 2013; Norén et al., 2013;
Ryan, Schuemie, Gruber, Zorych, & Madigan, 2013; Ryan, Schuemie, & Madigan, 2013;
Suchard et al., 2013).
In addition to the curated relative small reference sets, researchers have used the Side Effect
Resource (SIDER) to serve as a gold standard in a large scale to validate detected ADRs
or to evaluate drug-event signal detection systems (Deftereos et al., 2011; Saiakhov,
Chakravarti, & Klopman, 2013; Yates & Goharian, 2013). SIDER contains information
about the side effects of drugs that has been extracted from package inserts by text mining
tools. However, there is reason to believe that SIDER may include false drug/ADR
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associations, which would lead to inaccurate evaluation of the systems concerned. It has
been argued that package inserts over-report with respect to side effects (Duke J et al.,
2011). Analysis of SIDER has shown that text mining errors may occur when processing
the package insert; for instance, generic warnings have been mistakenly extracted from
labeling information (Kuhn et al., 2013).
Therefore, to use a large scale reference standard in pharmacovigilance evaluation, it is of
interest to determine the extent to which the side effects reported in SIDER occur in
practice. By limiting to the side effects that have sufficient representations in practice, false
drug/ADR associations can be eliminated from SIDER and the predictive power of
pharmacovigilance methods can be less affected by inadequate sample size of drugs or
events. The information of practice usage can be obtained from a post-marketing SRS. A
SRS is designed to collect anecdotal case reports. Even though they are not peer-reviewed,
the case reports in SRSs can provide supporting evidence for possible drug/ADR
associations (J. K. Aronson & Hauben, 2006). These collected data represent suspected
drug/ADR associations reported by healthcare practitioners that observed a reaction in a
patient under their care, by pharmaceutical companies that are mandatory required to report
any collected side effects, or by consumers that may experience unpleasant reactions for
drug treatments. Therefore, these reports provide anecdotal evidence that a side effect
mentioned in a repository has occurred in practice.
In this study, I evaluate the frequency with which SIDER2 (SIDER version 2) drug/ADR
associations occur in reports submitted to the Food and Drug Agency (FDA) Adverse Event
Reporting System (FAERS). The ultimate goal of this research is to develop a drug/ADR
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reference set consisting of those label-derived side effects that have been observed in
practice, for the purpose of pharmacovigilance research.

5.1 Materials
SIDER2 is a publicly available database containing information on marketed medicines
and their known adverse reactions (Campillos, Kuhn, Gavin, Jensen, & Bork, 2008; Kuhn
et al., 2010). The current version (SIDER2) was released in 2012, and was used for this
study. The information in SIDER2 was extracted from drug labeling information (package
inserts) using text mining tools and a side effects dictionary. The source of package inserts
includes British Columbia Cancer Agency, Facts@FDA, FDA Center for Drug Evaluation
and Research, FDA MedWatch, and Health Canada Drug Product Database (DPD).
Labeling information is from clinical trials, post-marketing surveillance, etc. To construct
the side effects dictionary (Kuhn et al., 2010), Coding Symbols for Thesaurus of Adverse
Reaction Terms (COSTART) was used as a seed dictionary and then was expanded by
extracting synonyms for the seed dictionary from the Unified Medical Language System
(UMLS). To build SIDER drug-event associations, the drugs’ indications and side effects
related sections were processed to extract terms that correspond to the side effects
dictionary and the terms extracted from indications were subsequently excluded from
drugs’ side effects. SIDER2 contains 99,423 drug-event associations for 996 drugs and
4192 side effects.
FAERS is a spontaneous reporting system database that contains information on adverse
event and medication error reports that were submitted to the FDA by pharmaceutical
companies, health professionals and consumers in the United States (Center for Drug
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Evaluation and Research & U.S. Food and Drug Administration, 2012). FAERS database
contains 332,346 distinct strings in the “drug name” field, and 16,272 distinct strings in the
“reaction” field within 4,070,077 reports collected between 2004 to 2012 Q3. MetaMap is
a widely-used NLP tool that identifies concepts from the UMLS in biomedical text (A. R.
Aronson & Lang, 2010; A. R. Aronson, 2001).

5.2 Methods
5.2.1 Import SIDER2 and FAERS data in database
SIDER2 was downloaded and imported into a local database. Distinct drugs and side
effects were retrieved from the “meddraAvderseEffects” table. Publicly available FAERS
quarterly data files (2004 to 2012) were downloaded from the FDA website (Center for
Drug Evaluation and Research & U.S. Food and Drug Administration, 2014). I imported
all data into a SQL database aside from the 2012q4 data, since the metadata used in this
quarter were inconsistent with the database as a whole. The database contain 4,070,077
FAERS reports. For this study, I used information in the “Drug” and “Reaction” tables.
5.2.2 Parsing drug and side effect terms using MetaMap (Figure 5-1)
2013 edition of MetaMap (MetaMap 2013 was used to process and annotate retrieved drugs
and reactions and map them to UMLS concepts (U. S. National Library of Medicine, 2009)
for the purpose of mapping between FAERS and SIDER2. MetaMap identifies matches
between terms in text and candidate concepts from the UMLS. Each of these candidates is
annotated with a confidence score, a Concept Unique Identifier (CUI), a preferred label,
and one or more semantic types. The semantic types indicate the type of the concept.
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Examples include “Pharmacologic Substance” or “Diagnostic Procedure”. Candidates can
be assigned multiple semantic types.
I manually reviewed distinct semantic types or semantic type combinations for MetaMap
processed SIDER2 drugs and side effects and found out two features of drugs or side effects
relevant semantic types. First, there are semantic types that are irrelevant to my research,
such as “Organ or Tissue Function”, “Organism”, or “Activity”. Candidates of those
semantic types were excluded. Second, a combination of semantic types could often
contribute a more relevant classification. For example, the semantic type “Immunologic
Factor” occurred very frequently and often was associated with concepts that were not
relevant to drugs. However “Immunologic Factor” in combination with “Pharmacologic
Substance” provided more insight, and identified a relevant candidate in the context of our
study. Another example of semantic type combinations is a concept annotation that has a
candidate with only one semantic type having a higher confidence score and a candidate
with semantic type combinations having a less confidence score. The manual review
revealed that candidates with combinations of certain semantic types yielded more relevant
concepts. Consequently, restricting the result list by only accepting very specific semantic
types or combinations may increase the relevance of the concepts identified by MetaMap
to the study.
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Figure 5-1: The procedure for mapping SIDER2 and FAERS

5.2.3 Mapping between SIDER2 and FAERS
After annotating SIDER2 and FAERS with selected semantic types or semantic type
combinations, corresponding CUIs were retrieved and used to find the matched FAERS
drugs or ADRs for parsed SIDER2 drugs or ADRs. Figure 5-2 illustrates this process using
the example drug “dipyridamole”. For this drug, 78 FAERS drug inputs were found.
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Figure 5-2: Procedure of mapping SIDER2 drugs/side effects to FAERS drugs/reactions
using “dipyridamole” as an example

5.2.4 Retrieve number of reports for mapped SIDER2 drug-side effect pairs and
perform disproportionality analysis to find significant SIDER2 drug/ADR
associations
For each SIDER2 drug-side effect pair, I retrieved the number of related FAERS reports
through their mapped FAERS drugs or reactions. Then I constructed a contingency table
for each drug-side effect association with corresponding FAERS terms. Disproportionality
measures were used to calculate the significance of the association between drug and side
effect pairs co-occurring in the FAERS reports. These methods operate under the
assumption that if a drug causes a side effect, this drug and this event are more likely to
appear together than random combinations of drugs and suspected adverse events in the
SRS reports (Cao et al., 2005).
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Routinely used disproportionality measures for pharmacovigilance drug-side effect signal
detection include the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR),
Yule’s Q, and relative risk (RR) (Balakin & Ekins, 2009; Cao et al., 2007; Emmanuel Roux
et al., 2005; van Puijenbroek et al., 2002). In addition to these measure, I applied Chisquare test with the False Discovery Rate (FDR), which was introduced to measure the
multiple-hypothesis testing error and has been successfully used in large-scale genomic
studies to control false positive results (Benjamini & Hochberg, 1995; J. D. Storey &
Tibshirani, 2003; J. D. Storey, 2002).
5.2.5 Performance measure
Descriptive statistics of agreement for drug-side effect relationships between SIDER2 and
FAERS were estimated. We also conducted a manual review of a random sample of 60
pairs that occurred in SIDER2 without accompanying FAERS reports, to investigate the
cause of this mismatch. DailyMed was used to retrieve drug package inserts and review
the “Adverse Drug Reaction” section to track down the side effect of interest. MEDLINE
was queried to find published literature or case reports that relate to the drug/ADR pairs
retrieved from the package inserts.

5.3 Experimental design
To identify the subset of SIDER2 drug/ADR pairs that have been reported in practice, I
compare these pairs with anecdotal evidence from FAERS reports (Figure 5-3). To map
SIDER2 drugs to text in the FAERS “drug” field, and SIDER2 side effect to text in the
FAERS “reaction” field, MetaMap 2013 was used to process all terms and a manual review
process of selecting related semantic types that (Figure 5-1) was used to select appropriate
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UMLS candidates. Multiple disproportionality analysis methods (A. R. Aronson & Lang,
2010; A. R. Aronson, 2001; Center for Drug Evaluation and Research & U.S. Food and
Drug Administration, 2012) were then applied to analyze the significance of co-occurring
drug-side effect associations. The significantly reported SIDER2 drug/ADR associations
that are detected by all disproportionality measures are considered as a pharmacovigilance
reference standard.

Figure 5-3: Study design for decreasing false SIDER2 drug-side effect associations

5.4 Results
5.4.1 Concept extraction
Using the mapping procedure, I mapped 99% (986/996) of SIDER2 drugs and 97%
(4072/4192) of SIDER2 side effects to UMLS concepts; 78% of FAERS drug strings
(259,806 drugs) and 98% of FAERS reaction strings (15,989 reactions) to UMLS concepts.
Among SIDER2 mapped UMLS concepts, 969 drugs and 3853 side effects were mapped
to FAERS drug and reaction inputs. These concepts constituted 94.85% (94,306) of the
SIDER2 drug/ADR pairs, which were subsequently compared with FAERS reports. Of
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these 94,306 SIDER2 drug-side effect pairs, 11,306 pairs do not co-occur in FAERS
reports. 83,000 drug/ADR pairs have co-occurring reports in FAERS database.
For this study I only included reports that were related to these UMLS concepts.
Consequently, 4,070,225 reports were used for disproportionality analysis.
5.4.2 Reported SIDER side effects
I analyzed the frequency distribution of reports related to 83,000 SIDER2 drug/ADR pairs
that have co-occurred in FAERS reports (Figure 5-4). The number of FAERS reports
ranges from 1 to 360,146, with mean of 1944, median of 85, 1st quartile at 14, and 3rd
quartile at 598. The histogram of representing all pairs has long right tail and data are
skewed. For a more granular picture of this distribution, I plotted the histogram for each
quartile (Figure 5-4). Most drug/ADR pairs have a relatively small number of FAERS
reports and less than 600 FAERS reports.
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Figure 5-4: Frequency distribution of SIDER2 drug/ADR pairs (y-axis) that are grouped
by the number of FAERS reports that contain the drug/ADR of interest (x-axis)

5.4.3 Statistically significant drug/ADR pairs detected by disproportionality
measures
I evaluated the significantly reported instances of SIDER2 drug/ADR associations by
applying disproportionality measures using FAERS data (Table 5-1). About 60% to 80%
of SIDER2 drug/ADR pairs met the thresholds for significance of these statistical
measures. 46,203 SIDER2 pairs (904 drugs, 2984 side effects) were detected as statistically
significant by all statistical metrics.
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Table 5-1: The percentage of statistically significant SIDER2 drug/ADR pairs using
disproportionality measures
ROR-1.96SE>1 PRR-1.96SE>1 YulesQIC-2SD>0
Chi-Square test
1.96SE>0
with FDR (q
Value<0.05)
60%
60.9%
61.4%
55.7%
79.7%
(50,139/83,000) (50,570/83,000) (50,978/83,000) (46,209/83,000) (66,178/83,000)

5.4.4 Manual review sample drug/ADR pairs without case reports
I randomly selected 60 drug/ADR pairs from 11,306 pairs that were not included in any
FAERS report and analyzed possible reasons for why there are no case reports (Figure 55). Only 25 pairs were listed as side effects in the drug labeling or package inserts. Among
those 25, eight side effects were listed as “infrequent side effects” or less than 1% of tested
patients. For three side effects, the trial provided limited evidence whether they were
caused by the drug under trial. In two instances (cidofovir related hypophosphatemia and
glycosuria), participants were on several other medications and so it is difficult to establish
the causal relationships. In another instance (teniposide related arrhythmia), there was only
one report of this complication during pre-marketing trials, it was presumed rather than
confirmed clinically, and it had occurred in an elderly patient with a variety of other health
problems. Another six pairs among the 25 pairs had either mild side effects (e.g. dry throat,
dizziness), or concerned a rarely prescribed drug (e.g. maraviroc). I could not find a
plausible explanation for the remaining eight side effects that did not occur in any FAERS
report; these side effects were listed in “Adverse Reactions” section for different systems
without frequency information in the package inserts.
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Among the remaining 35 drug/ADR pairs, six did not concern drugs; they instead
concerned a vitamin or some other chemical component. So no package insert was
available specifically the six chemical components (e.g. 1,25-dihydroxyvitamin D3,
betaine). For seventeen pairs package inserts were available, but the labeling does not list
the side effects concerned. Four pairs suggested a possible text mining error, as SIDER2
side effect was close to the information in the labelling either conceptually or
orthographically, but is, in fact, not a match. For four pairs that are drugs (e.g. ofloxacin),
I couldn't find the package insert in the DailyMed database.

3
8

6

Not drug

4

No labeling

1

Not listed in labeling
NLP error

5

Listed in labeling
Listed in labeling but minor ADR

17
Infrequent prescribed drug

8

Listed in labeling, infrequent ADR
Listed in labeling, unclear causal relationships

8

Figure 5-5: Interpretation of 60 randomly selected SIDER2 pairs without any supporting
reports

5.5 Discussion
The study suggests that a higher precision subset of SIDER2 pairs could be identified by
filtering out possible false positives using an inclusion criterion based on statistically
significant association in the FAERS data. These false positives may result from NLP
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errors during the parsing of drug labeling or inserts; on account of the inclusion of
infrequent side effects that were not conclusively linked to the drug, but nonetheless
occurred during clinical trials; or for other reasons. For the evaluation of new methods in
pharmacovigilance it is imperative to use a high quality data set. If a data set used as a gold
standard contains uncertainties itself the performance assessment of a new system or
algorithm against these data set is difficult. It cannot be clearly concluded as to why the
results of a new method show a certain outcome. Both a bias towards good or bad results
could be caused by the quality of the reference data rather than by the method itself.
Furthermore, in the case of machine learning systems trained on these data, the inaccuracies
inherent in the data set may impair the performance of the derived models.
There are some limitations to this study. With the mapping procedure, it frequently
occurred that input strings, specifically those of reactions, were mapped to multiple
concepts. This was the case when either no concept existed that expressed the entirety of
the input, or MetaMap simply could not recognize it. For example, “carcinoma of the small
bowel” exists as a concept in and of itself, even though it is a combination of carcinoma as
a clinical observation and small bowel as a body location. On the other hand, for “splenic
embolism” MetaMap lists a candidate concept for each of embolism and spleen. The
spleen, which is of semantic type “Body Part, Organ, or Organ Component” is certainly
not an appropriate result for splenic embolism, while the embolism itself is too general as
it may appear at other body sites also. So rather than accepting “embolism” by itself, a
combination of those two concepts would be most appropriate. The main concept,
embolism in the example, and one or more concepts that contribute, modify, or tag the
main concept could be combined. Similarly, for the input string “neutrophil count
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increased” MetaMap detects “neutrophil count” as “Laboratory Procedure” and
“increased” as “Quantitative Concept” but without connection to the neutrophil count.
Considering a combinations of concepts of different semantic types that MetaMap treats as
atomic units may improve the quality of our results.
It also has been argued that SRSs are vulnerable to bias, and that the ADR under-reporting
rate is considerable. Heterogeneity and bias result from different reasons: severe effects
were more reported than mild ones, and labeled adverse drug reactions are more likely to
be reported than unlabeled ones (Benjamini & Hochberg, 1995). The first of these findings
is supported by our interpretations of 60 randomly selected SIDER2 drug/ADR pairs
examined without FAERS reports, as some of these side effects were mild in nature. That
labeled side effects are more frequently reported supports our argument for the use of
FAERS reports as a means to validate drug/ADR repositories.
An important outcome of this study is a high-precision subset of SIDER2 in which reported
drug/ADR pairs are supported by the statistical significance of their FAERS reports. I
anticipate that this subset will be of value for the training and evaluation future
pharmacovigilance systems and new ADR signal detection algorithms.

5.6 Conclusion
Based on the consistency between FAERS and SIDER2 drug/ADR associations, a
drug/ADR reference set is retrieved. The utility and application of the reference set will be
further evaluated in pharmacovigilance research.
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Chapter 6: Improving Signal Detection from the Electronic Health Records by
Using Literature Based Discovery
In previous experiments, I demonstrated that (1) possible drug/ADR signals can be detected
from EHR data; and (2) LBD models based on methods of distributional semantics can
identify plausible ADRs. In this experiment, I test my unifying hypothesis that signal
detected from EHR data can be improved by integrating knowledge from the literature.
Specifically, I propose that the performance of signal detection from the EHR can be
improved by reranking the detected signals using LBD models based on distributional
semantics. I evaluate this procedure using the drug/ADR reference set that we developed
from SIDER2 and FAERS, as well as with SIDER2 itself.

6.1 Experimental design (Figure 6-1)
In Chapter 3, I described how Drug/ADR signals were detected from EHR data hosted in
a Clinical Data Warehouse (CDW) using several disproportionality measures and other
statistical tests. The best performing statistical model from those experiments was chosen
for this one. Likewise, the best performing LBD model from the experiments described in
Chapter 4 was utilized for this experiment. To perform the experiment, drug/ADR signals
were detected in EHR data using the statistical model and ranked in accordance with the
strength of their associations (according to the statistical model). These drug/ADR signals
are referred to as pre-reranking drug/ADR signals. Subsequently, these signals were
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reranked in accordance with the similarity scores (the measure for plausibility) that the
LBD distributional model estimated from the relatedness between drugs and ADRs across
the set of discovery patterns identified in the experiments described in Chapter 4.
Consequently, these are referred to as post-reranking drug/ADR signals. They were then
evaluated by comparing the pre- and post-drug/ADR signals to both SIDER2 and a
reference set that we developed from it.

Figure 6-1: Overall research design for reranking statistically significant drug/ADR
associations by similarity scores

6.2 Materials and Methods
6.2.1 Models selected for this study
I have elaborated methodologies for statistical data mining from EHR and LBD
distributional semantics in Chapter 3 and Chapter 4, respectively. Of these methods, the
Chi-square statistics with FDR (for estimating the statistical significance of observed
114

associations) and PSI double+triple group were best performing models in their respective
experiments, and consequently were utilized for this one.
In pre-reranking drug/ADR signals, the chi-square score is used as to reflect the statistical
strength of the association observed in CDW data. The FDR-based q values are used as a
significance threshold, to predict if the signal is true or false. Similarity scores from PSI
double+triple model are used to rerank those signals that fell above the q-value threshold.
6.2.2 Experimental reference standards and test dataset
I evaluated the above models using two reference standards – side effect resource
(SIDER2) and the reference set I developed using SIDER2 and FDA adverse event
reporting system (FAERS, as described in Chapter 5). The reference set is relatively small
and contains only those SIDER2 relationships that frequently occurred in SRS databases.
For each reference standard, its drugs and side effects that are not only contained in the
CDW EHR data but also represented in the PSI model were eligible for this experiment.
This resulted in a set of 811 drugs and 1879 ADRs with SIDER2 and 773 drugs and 1374
ADRs with the reference set (Table 6-1). Among these, only the predicted positive pairs
by Chi-square statistics with FDR as statistically significant associations were utilized for
the analysis.

Table 6-1: SIDER2 and a Reference Set are used to construct the dataset for the
experiment
Group
Drugs ADRs True
False
Total
Statistically True
Pairs
Pairs
Pairs
significant
positives in
associations statistically
significant
associations
SIDER2
811
1879 260,555 395,468 436,865 260,555
28,114
115

Group

Drugs ADRs True
Pairs

Reference 773
Set

1374

40,838

False
Pairs

Total
Pairs

Statistically True
significant
positives in
associations statistically
significant
associations
315,544 356,382 215,024
27,765

6.2.3 Performance metrics
Average precision (AP) is the average of the precision that is measured at the rank at which
each correct prediction is retrieved. Precision at 100 (Manning et al., 2008) is the precision
at the first 100 retrieved results. A true positive drug/ADR association, defined as
“rediscovery”, is an adverse effect that is confirmed by SDIER2 or the reference set. The
median rank of rediscoveries across statistically significant drug/ADR associations
approximates the point in the ranked list that half of the known adverse effects were
recovered by Chi-square statistics with FDR or PSI-double+triple model.
AP, precision at 100, and median rank of rediscoveries are calculated and compared
between pre- and post- reranking for the two datasets. A two-sample Kolmogorov-Smirnov
test was conducted to evaluate if there is a significant difference for the total number of
rediscoveries at each rank between pre- and post-reranking signals. The rediscovery at each
rank is also plotted for different dataset.
To measure the performance with respect to the true positive rate (TPR) and false positive
rate (FPR), receiver operating characteristic (ROC) curve was plotted for statistically
significant drug/ADR associations. Subsequently, an area under the ROC curve (AUROC)
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from the ranking of each model and an area for precision and recall (AUC for PrecisionRecall) were calculated using AUCCalculator (Davis & Goadrich, 2006).

6.3 Results
6.3.1 Performance
Results of comparing pre-reranking and post-reranking for different datasets are shown in
Table 6-2. PSI-based models perform better than RRI-based models and both models
perform better than the random baseline.

Table 6-2: Results of precision and rank-based measures for different groups and
different datasets
Test Set
Group
MAP
Precision Median
AUC for
AUROC
at 100
Rank
PrecisionRecall
SIDER2
Pre0.1424 0.16
103,528
0.1411
0.5708
reranking
(Chi)
Post0.1640 0.21
85,166
0.1639
0.6323
reranking
(Similarity)
Reference PreSet
reranking
(Chi)
Postreranking
(Similarity)

0.1655

0.19

87,218

0.1641

0.5664

0.1847

0.21

75,197

0.1846

0.6173
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With the SIDER2 dataset, the median rank of true positives with EHR data (pre-reranking
signals) is 103,528; and in combination with the LBD model (post-reranking signals) it is
85,166. With the reference set, the median rank of true positives in pre- and post-reranking
signals is 87,218 and 75,197, respectively. Two-sample Kolmogorov-Smirnov test shows
there is a significant difference of the accumulated number of true positives at each rank
(Figure 6-2) between pre- and post- reranking methods for both datasets (all P-value <
2.2e-16).

Figure 6-2: Comparing accumulated number of true positives for each ranking between
pre- and post-reranking signals for SIDER2 set (top) and the Reference set (bottom)
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6.3.2 AUC
Figures 6-3 and 6-4 present the global ROC curves. ROC curve shows the tradeoff between
sensitivity and specificity. The AUC provides a cumulative estimate of accuracy, and is
shown for each model in Table 6-2. With respective dataset, AUROC of post-reranking
method is greater than the pre-reranking method.

Figure 6-3: ROC plot of true positive rate and false positive rate for pre- and postreranking groups for SIDER2 set
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Figure 6-4: ROC plot of true positive rate and false positive rate for pre- and postreranking groups for the Reference set

6.4 Discussion
In this experiment, drug/ADR signals that were predicted from EHR data using the best
performing statistical algorithm were reranked using the PSI model. This resulted in
significant increases of the true positive rate at a corresponding rank (in comparison to the
true positive rate with no reranking). Precision and AUC are better performed with postreranking method. The experiment demonstrates that the PSI model can filter noisy signals
using a measure of the plausibility of the relationship between the drugs and ADRs
concerned.
Overall, based on what I have learned from the series of experiments, I want to propose the
architecture for a plausibility-based pharmacovigilance system (Figure 6-5). This
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framework describes the essential steps: (1) Process EHR data to extract coded drugs and
possible problems; a NLP tool is required for processing unstructured clinical notes. (2)
Select a cohort for drug/ADR analysis. (3) From the drug/problem candidates, existing
known relationships knowledge is used to filter the known drug/problem relationships. (4)
Conducting statistical analysis for drug/problem candidates and identifying statistically
significant drug/ADR associations. (5) Using the PSI model to justify plausible drug/ADR
associations and filtering the statistically detected signals using their plausibility. (6)
Present plausible drug/ADR signals and their evidence retrieved by the PSI model to
clinicians or practitioners for review. (7) Automatically submit the detected drug/ADR
signals with all related clinical information to PV health administrative departments. This
helps clinicians in making clinical decision for the patients that are taking the relevant
drugs.

6.5 Conclusion
This experiment supports my overall hypothesis that the precision of signal detection
from EHR data can be improved by integrating knowledge from the biomedical literature.
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Figure 6-5: The proposed architecture for a plausibility-based pharmacovigilance system

Chapter 7: Key Findings, Innovation, Contributions, Future work and Conclusions
7.1 Overview and summary of key findings
For this thesis I conducted four experiments. First, of all the SIDER2 ADRs that occur in an
outpatient EHR system, I was able to detect 10-15% in that EHR data by using existing
disproportionality measures and Chi-square statistics with FDR. The Chi-square statistics with
FDR was demonstrated as the best performing model with an F-measure of 0.1826, evaluated
against SIDER2. Second, I built two LBD models based on scalable methods of distributional
semantics (RRI and PSI discovery patterns) to identify possible drug/ADR associations utilizing
the biomedical literature. The PSI discovery patterns model outperforms the RRI co-occurrence
based model and can be used to evaluate the plausibility of drug/ADR associations. It has the
additional advantage of modeling the relations between the involved medical concepts. Third, as
a consequence of possible false associations that exist in the SIDER side effects dataset used for
evaluation, I constructed a drug/ADR reference set. This reference set is based on the consistency
between FAERS and the SIDER data set. I then used this as an additional reference set for
evaluating side effects. Fourth and last, I applied a plausibility measure obtained through PSI
discovery patterns to rerank the statistically significant drug/ADR associations detected in EHR
data, which improved the precision against SIDER2 and the newly developed reference set. This
verified my overall hypothesis that using literature to justify plausibility can improve the quality
of signal detection from EHR data.
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7.2 Innovation
I have developed means to partially automate the signal evaluation process by integrating
knowledge extracted from the biomedical literature with possible drug/ADR signals derived from
EHR data using statistical methods. To do so, recent LBD methods using “discovery patterns”
were adapted to the task of evaluating the plausibility of drug/ADR signals at scale. To the best of
my knowledge, this is the first time knowledge from the biomedical literature has been integrated
with EHR data for signal detection. Previous attempts at applying methods of literature based
discovery to find possible mechanisms to explain drug/ADR associations were conducted using
manually defined discovery patterns. My research describes a method to automatically define
pharmacovigilance related discovery patterns from the literature, and applies those to find
predication-based explanations in an automated way on a large scale.
In summary, this research is the first to integrate semantic predications into the signal detection
process to provide evidence supporting the plausibility of the connection between drugs and
ADRs. The automated evaluation of plausibility to support causality according to the meaning
defined by the Bradford-Hill criteria, is a novel contribution to the field of pharmacovigilance and
to signal detection in general.

7.3 Theoretical contribution
From a theoretical perspective, my work is motivated by the notion of abductive reasoning as
described by American philosopher CS Peirce (Peirce, 1955). According to Peirce, abductive
reasoning (Schvaneveldt & Cohen, 2010) is the process of seeking the best possible explanation
for an observation. The observation is a given and it is the goal to find an explanation that is
124

sufficient to justify the presence of the observation. This is in contrary to deductive reasoning
where from a given starting condition possible consequences are deduced. It is also important to
note the difference between a sufficient and a necessary condition. A sufficient explanation serves
to explain an observation but its presence is not necessary. Thus, the observation can still be
explained by other conditions and one explanation does not explicitly exclude others.
Currently in PV, signals indicating possible causal associations are discovered within a large
database and then manually evaluated. A problem with this approach is that mined associations
can be relevant or irrelevant, or may even be negative associations. Exhaustive manual review of
these potential signals is not feasible. In my research I abduce explanations in an automated way,
or, in other words, propose and find logical explanations for the identified associations in an
automated way. The theoretical value added is then to use the generated explanations to
collectively assess a measure for the plausibility of an association. The theoretical contribution is
constituted by not primarily focusing on finding explanatory hypotheses but by focusing on
assessing the plausibility of an observation. Where abductive reasoning is concerned with finding
truthful explanations for an observation, my framework adds to that by going a step further and
also assessing the truthfulness of the observation itself.

7.4 Practical contribution
Practically, the detection of signals from EHR data has the potential to improve post-marketing
drug surveillance in real world applications. The computational requirements of the employed
algorithms and tools are sufficiently low to allow for delivery of results in real time. In this context,
“real time” effectively means timely surveillance, and thus the early detection of ADRs that are
potentially harmful to patients. In the concluding experiment I showed that augmenting statistical
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associations with a plausibility measure enhances the identification of known ADRs, suggesting
that this approach would also lead to more accurate identification of novel ADRs. Furthermore,
delivery of the underlying explanatory hypotheses to domain experts has the potential to increase
the efficiency of the critical clinical review process. This is because the number of associations
that is mined from EHR data is very high, and these signals still have to be manually evaluated.
Prioritizing signals automatically has the potential to speed up the review process. Noise can be
separated from those signals supported by plausible evidence because of the evidence provided to
researchers or practitioners. Moreover, the evidence provided is in a very concise format (at the
predication level rather than the document level) that allows for the exploration of a large amount
of evidence in an efficient manner.
With respect to informatics in general, the methods and procedures of integrating formal
knowledge can be generalized and applied to other domains. With the rapid growth of use of EHR
data for clinical research (Hripcsak & Albers, 2013), new findings can be learned from the EHR
data. The PSI discovery patterns model can be adapted and used to provide the automated
interpretation of the findings. A very interesting example is outbreak surveillance, for which a
timely identification of plausible signals is essential. For example, an influenza outbreak can be
identified from EHR data by mining abnormal lab results, symptoms and outpatient diagnoses. PSI
discovery patterns can retrieve possible sources, mode of transmission and risk factors (CDC,
2006) by analyzing the plausible pathways between the virus and the disease/symptoms. This can
assist field investigators’ work.
In summary, the detection of signals from EHR data and the subsequent evaluation using
supporting evidence from literature with PSI discovery patterns in pharmacovigilance on a large
scale in an automated way has not been done before and has shown good results. The methods and
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procedures proposed and examined in this work are novel to the field of pharmacovigilance and
applicable to other informatics areas.

7.5 Future work
In future work, I plan to improve my methods for the estimation of plausibility, and provide better
ways for domain experts to explore the evidence that supports the explanatory hypotheses the
methods generate. Although predications are a concise way to present supporting evidence
gathered by PSI discovery patterns from the medical literature, the presentation to domain experts
for review in a concise way still presents a challenge. Since evidence is retrieved based on
predications which can naturally be built into a graph network, it is straightforward to examine if
graph algorithms can be utilized to analyze the evidence network. This can result in prioritization
or the identification of important biological factors, or even biological pathways. Subsequently,
improved visualizations could highlight specific aspects like biological factors and pathways and
could put an emphasis on important concepts through their connectedness for example. This would
add to the efficacy of the manual review process.
The methods developed for my research have the potential to support a real-time PV system. This
work has demonstrated that signal detection and signal evaluation can be done in a partially
automated and therefore, potentially more timely manner. I will continue working in this direction
with the aim to contribute to the development of an active drug surveillance system.

7.6 Conclusions
This thesis demonstrates that drug/ADR associations can be detected from unstructured outpatient
clinical notes by using statistical mining algorithms. PSI discovery patterns can further improve
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the precision of detected signals by leveraging knowledge from literature and modeling the
plausibility of the identified associations. Consequently this work has extended the state of the art
in EHR-based pharmacovigilance and contributed new ideas that pave the way for further studies
with the potential to further enhance the field of pharmacovigilance and drug safety.
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